ÌåäÓíèâåð - MedUniver.com Âñå ðàçäåëû ñàéòà Âèäåî ïî ìåäèöèíå Êíèãè ïî ìåäèöèíå Ôîðóì êîíñóëüòàöèé âðà÷åé  
Ðåêîìåíäóåì:
Ïåäèàòðèÿ:
Ïåäèàòðèÿ
Ãåíåòèêà â ïåäèàòðèè
Äåòñêàÿ àëëåðãîëîãèÿ è èììóíîëîãèÿ
Äåòñêàÿ ãàñòðîýíòåðîëîãèÿ
Äåòñêàÿ ãåìàòîëîãèÿ
Äåòñêàÿ ãèíåêîëîãèÿ
Äåòñêàÿ äåðìàòîëîãèÿ
Äåòñêàÿ è ïîäðîñòêîâàÿ ñòîìàòîëîãèÿ
Äåòñêàÿ êàðäèîëîãèÿ
Äåòñêàÿ íåâðîëîãèÿ
Äåòñêàÿ íåôðîëîãèÿ
Äåòñêàÿ îíêîëîãèÿ
Äåòñêàÿ îðòîïåäèÿ
Äåòñêàÿ îòîðèíîëàðèíãîëîãèÿ
Äåòñêàÿ îôòàëüìîëîãèÿ
Äåòñêàÿ ïóëüìîíîëîãèÿ
Äåòñêàÿ ðåàáèëèòàöèÿ
Äåòñêàÿ ðåâìàòîëîãèÿ
Äåòñêàÿ óðîëîãèÿ
Äåòñêàÿ ôàðìàêîëîãèÿ
Äåòñêàÿ ýíäîêðèíîëîãèÿ
Èíôåêöèîííûå áîëåçíè ó äåòåé
Íåîíàòîëîãèÿ
Íåîòëîæíûå ñîñòîÿíèÿ äåòåé
Ïîäðîñòêîâàÿ ìåäèöèíà
Ðîñò è ðàçâèòèå ðåáåíêà
Îðãàíèçàöèÿ ïåäèàòðè÷åñêîé ïîìîùè
Ôîðóì
 

Àâòîðû òðóäîâ (ñòàòåé) èñïîëüçîâàííûå ïðè ïîäãîòîâêå ìàòåðèàëîâ ïî äåòñêîé ýêîëîãèè â ïåäèàòðèè

 ñòàòüÿõ íà ñàéòå èñïîëüçîâàíû ñëåäóþùèå ñîêðàùåíèÿ:

  • °F — òåìïåðàòóðà ïî Ôàðåíãåéòó
  • °C — òåìïåðàòóðà ïî Öåëüñèþ
  • 5-ÍÒ — 5-ãèäðîêñèèíäîëóêñóñíàÿ êèñëîòà ìî÷è
  • ÀÁ — àíòèáèîòèê(è)
  • ÀÁËÀ — àëëåðãè÷åñêèé áðîíõîëåãî÷íûé àñïåðãèëëåç
  • ÀÁÒ — àíòèáàêòåðèàëüíàÿ òåðàïèÿ
  • ÀÂ — àòðèîâåíòðèêóëÿðíûé
  • ÀÃ — àðòåðèàëüíàÿ ãèïåðòåíçèÿ
  • ÀÃí — àíòèãåí
  • ÀÄ — àðòåðèàëüíîå äàâëåíèå
  • ÀÄà — àíòèäèóðåòè÷åñêèé ãîðìîí
  • ÀÄÑ — àíàòîêñèí äèôòåðèéíî-ñòîëáíÿ÷íûé
  • ÀÄÑ-Ì — àíàòîêñèí äèôòåðèéíî-ñòîëáíÿ÷íûé (ìàëûå äîçû)
  • ÀÄÔ — àäåíîçèíäèôîñôîðíàÿ êèñëîòà, àäåíîçèíäèôîñôàò
  • ÀÊÄÑ — àíàòîêñèí êîêëþøíî-äèôòåðèéíî-ñòîëáíÿ÷íûé
  • ÀÊÒÃ — àäðåíîêîðòèêîòðîïíûé ãîðìîí
  • ÀÊØ — àîðòîêîðîíàðíîå øóíòèðîâàíèå
  • ÀËÒ — àëàíèíàìèíîòðàíñôåðàçà
  • àìåð. — àìåðèêàíñêèé
  • ÀÌÊ — àçîò ìî÷åâèíû êðîâè
  • ÀÌÔ — àäåíîçèíìîíîôîñôîðíàÿ êèñëîòà, àäåíîçèíìîíîôîñôàò
  • ÀÍÀ — àíòèíóêëåàðíûå àíòèòåëà
  • àíàò. — àíàòîìè÷åñêèé
  • àíãë. — àíãëèéñêèé
  • ÀÏÔ — àíãèîòåíçèí-ïðåâðàùàþùèé ôåðìåíò
  • ÀÐÂÒ — àíòèðåòðîâèðóñíàÿ òåðàïèÿ
  • ÀÐÏ — àêòèâíîñòü ðåíèíà â ïëàçìå êðîâè
  • ACT — àñïàðòàòàìèíîòðàíñôåðàçà
  • ÀÒë — àíòèòåëî
  • ÀÒÔ — àäåíîçèíòðèôîñôîðíàÿ êèñëîòà, àäåíîçèíòðèôîñôàò
  • ÀóÄ — àóòîñîìíî-äîìèíàíòíûé
  • ÀóÐ — àóòîñîìíî-ðåöåññèâíûé
  • ÀÔÏ — α-ôåòîïðîòåèí
  • ÀÔÑ — àíòèôîñôîëèïèäíûé ñèíäðîì
  • ÀÕÝ — àöåòèëõîëèíýñòåðàçà
  • ÀÖÕ — àöåòèëõîëèí
  • À×Ò — àêòèâèðîâàííîå ÷àñòè÷íîå òðîìáîïëàñòèíîâîå âðåìÿ
  • ÁÀ — áðîíõèàëüíàÿ àñòìà
  • ÁÀÄ — áèîëîãè÷åñêè àêòèâíàÿ äîáàâêà
  • ÁÀË — áðîíõîàëüâåîëÿðíûé ëàâàæ
  • ÁÀÐ — áèïîëÿðíîå àôôåêòèâíîå ðàññòðîéñòâî (I èëè II òèïà)
  • ÁÊÊ — áîëüøîé êðóã êðîâîîáðàùåíèÿ
  • ÁËÄ — áðîíõîëåãî÷íàÿ äèñïëàçèÿ
  • ÁËÍÏà — áëîêàäà ëåâîé íîæêè ïó÷êà Ãèñà
  • ÁÌÑÝ — áþðî ìåäèêî-ñîöèàëüíîé ýêñïåðòèçû
  • ÁÏ — áðþøíàÿ ïîëîñòü
  • ÁÏÍÏà — áëîêàäà ïðàâîé íîæêè ïó÷êà Ãèñà
  • ÁÐÌ — áàçîâûå ðåàíèìàöèîííûå ìåðîïðèÿòèÿ
  • ÁÐÍÑ — áûñòðî ðàçðåøèâøååñÿ íåîáúÿñíèìîå ñîáûòèå
  • ÁÖÆ — áàöèëëà Êàëüìåòòà-Ãåðåíà â ò.÷. — â òîì ÷èñëå
  • ÁÔÏ - áèîôèçè÷åñêèé ïðîôèëü ïëîäà
  • â. — âåê
  • â/ — âíóòðè... â ñëîæíîñîñòàâíûõ ñëîâàõ (íàïð. â/ñîñóäèñòûé, â/÷åðåïíîé è ò.ï.)
  • â/à — âíóòðèàðòåðèàëüíî
  • â/â — âíóòðèâåííî
  • â/ê — âíóòðèêîæíî
  • â/ì — âíóòðèìûøå÷íî
  • ââ. — âåêà
  • â-âî — âåùåñòâî
  • ÂÂÝ — âîåííî-âðà÷åáíàÿ ýêñïåðòèçà
  • ÂÃÄ — âíóòðèãëàçíîå äàâëåíèå
  • ÂÃ× — âèðóñ ãåðïåñà ÷åëîâåêà
  • ÂÄÏ — âåðõíèå äûõàòåëüíûå ïóòè
  • ÂÆÊ — âíóòðèæåëóäî÷êîâîå êðîâîèçëèÿíèå
  • ÂÇÊ — âîñïàëèòåëüíûå çàáîëåâàíèÿ êèøå÷íèêà
  • ÂÇÎÌÒ—âîñïàëèòåëüíûå çàáîëåâàíèÿ îðãàíîâ ìàëîãî òàçà
  • ÂÈÏ — âàçîàêòèâíûé èíòåñòèíàëüíûé ïåïòèä
  • ÂÈ× — âèðóñ èììóíîäåôèöèòà ÷åëîâåêà
  • ÂÌÏ — âûñîêîòåõíîëîãè÷íàÿ ìåäèöèíñêàÿ ïîìîùü
  • ÂÌÑ — âíóòðèìàòî÷íîå ñðåäñòâî (ñïèðàëü)
  • ÂÍ — âèðóñíàÿ íàãðóçêà
  • ÂÍÑ — âåãåòàòèâíàÿ íåðâíàÿ ñèñòåìà
  • ÂΠ— Âåëèêàÿ Îòå÷åñòâåííàÿ âîéíà
  • ÂÎÃÌ — âûñîêîãîðíûé îòåê ãîëîâíîãî ìîçãà
  • ÂÎÇ — Âñåìèðíàÿ îðãàíèçàöèÿ çäðàâîîõðàíåíèÿ
  • ÂÎË — âûñîêîãîðíûé îòåê ëåãêèõ
  • ÂÎÌÊ — âðà÷, îñóùåñòâëÿþùèé ìåäèöèíñêèé êîíòðîëü
  • ÂÎÏ — âðà÷ îáùåé ïðàêòèêè
  • ÂÏÂ — âåðõíÿÿ ïîëàÿ âåíà
  • ÂÏÃ — âèðóñ ïðîñòîãî ãåðïåñà
  • ÂÏÐ — âðîæäåííûå ïîðîêè ðàçâèòèÿ
  • ÂÏÑ — âðîæäåííûé ïîðîê ñåðäöà
  • ÂÏ× — âèðóñ ïàïèëëîìû ÷åëîâåêà
  • ÂÐÒ — âñïîìîãàòåëüíûå ðåïðîäóêòèâíûå òåõíîëîãèè
  • ÂÑÎ — âîäíî-ñîëåâîé îáìåí
  • Â×Ä — âíóòðè÷åðåïíîå äàâëåíèå
  • Â×ÈÂË — âûñîêî÷àñòîòíàÿ èñêóññòâåííàÿ âåíòèëÿöèÿ ëåãêèõ (HFV)
  • ÂÝÁ — âèðóñ Ýïøòåéíà-Áàðð
  • ã — ãðàìì
  • ã. — ãîä
  • Ã-6-ÔÄ — ãëþêîçî-6-ôîñôàòäåãèäðîãåíàçà
  • ÃÀÌÊ — ãàììà-àìèíîìàñëÿíàÿ êèñëîòà
  • ÃÁ — ãèïåðòîíè÷åñêàÿ áîëåçíü
  • ÃÁÍ — ãåìîëèòè÷åñêàÿ áîëåçíü íîâîðîæäåííîãî
  • ÃÁÎ — ãèïåðáàðè÷åñêàÿ îêñèãåíàöèÿ
  • ÃÇÒ — ãèïåð÷óâñòâèòåëüíîñòü çàìåäëåííîãî òèïà
  • ãèñò. — ãèñòîëîãè÷åñêèé
  • ÃÊ — ãðóäíàÿ êëåòêà
  • ÃÊÌÏ — ãèïåðòðîôè÷åñêàÿ êàðäèîìèîïàòèÿ
  • ÃÊÑ — ãëþêîêîðòèêîñòåðîèä(û)
  • ÃËÃ — ãåìîôàãîöèòàðíûé ëèìôîãèñòèîöèòîç
  • ÃËÏÑ — ãåìîððàãè÷åñêàÿ ëèõîðàäêà ñ ïî÷å÷íûì ñèíäðîìîì
  • ÃÌ — ãîëîâíîé ìîçã
  • ÃÌ-ÊÑÔ — ãðàíóëîöèòàðíî-ìàêðîôàãàëüíûé êîëîíèåñòèìóëèðóþùèé ôàêòîð
  • ÃÌÔ — ãóàíîçèíìîíîôîñôàò
  • ÃíÐà — ãîíàäîòðîïèí-ðèëèçèíã-ãîðìîí
  • ÃÍÒ — ãèïåð÷óâñòâèòåëüíîñòü íåìåäëåííîãî òèïà
  • ÃÏÎÄ — ãðûæà ïèùåâîäíîãî îòâåðñòèÿ äèàôðàãìû
  • ÃÐÄÑ — ãèïîêñè÷åñêàÿ ðåàêöèÿ äûõàòåëüíîé ñèñòåìû ãðå÷. — ãðå÷åñêèé
  • ÃÒÔ — ãóàíîçèíòðèôîñôàò
  • ÃÓÑ — ãåìîëèòèêî-óðåìè÷åñêèé ñèíäðîì
  • Ãö — ãåðö
  • ÃÝÁ — ãåìàòîýíöåôàëè÷åñêèé áàðüåð
  • ÃÝÐ — ãàñòðîýçîôàãåàëüíûé ðåôëþêñ
  • ÃÝÐÁ — ãàñòðîýçîôàãåàëüíàÿ ðåôëþêñíàÿ áîëåçíü
  • äÁ — äåöèáåë
  • ÄÂÑ — äèññåìèíèðîâàííîå âíóòðèñîñóäèñòîå ñâåðòûâàíèå
  • ÄÃÒ — äèãèäðîòåñòîñòåðîí
  • ÄÄ — äèôôåðåíöèàëüíàÿ äèàãíîñòèêà, äèôôåðåíöèàëüíî-äèàãíîñòè÷åñêèé
  • ÄÄÁÀ — äëèòåëüíîäåéñòâóþùèå β2-àãîíèñòû
  • ÄÄÊ — äèôôåðåíöèàëüíî-äèàãíîñòè÷åñêèé êðèòåðèé (êðèòåðèè)
  • ÄÄÐÌ - äîïóñòèìûé äèàïàçîí ðàñïðåäåëåíèÿ ìàêðîíóòðèåíòîâ
  • ÄÈ — äîâåðèòåëüíûé èíòåðâàë
  • ÄÊ — äèàãíîñòè÷åñêèé êðèòåðèé
  • ÄÊÀ — äèàáåòè÷åñêèé êåòîàöèäîç
  • ÄÊÌÏ — äèëàòàöèîííàÿ êàðäèîìèîïàòèÿ
  • ÄÌÆÏ — äåôåêò ìåææåëóäî÷êîâîé ïåðåãîðîäêè
  • ÄÌÏÏ — äåôåêò ìåæïðåäñåðäíîé ïåðåãîðîäêè
  • ÄÌÑ — äîáðîâîëüíîå ìåäèöèíñêîå ñòðàõîâàíèå
  • ÄÍ — äûõàòåëüíàÿ íåäîñòàòî÷íîñòü
  • ÄÍÊ — äåçîêñèðèáîíóêëåèíîâàÿ êèñëîòà
  • ÄÍÒ — äåôåêòû íåðâíîé òðóáêè
  • ÄÎ - äûõàòåëüíûé îáúåì
  • ÄÎÔÀ — äèãèäðîêñèôåíèëàëàíèí
  • ÄÏ — äûõàòåëüíûå ïóòè
  • ÄÏÊ — äâåíàäöàòèïåðñòíàÿ êèøêà
  • ÄÏÌ — äàòà ïîñëåäíåé ìåíñòðóàöèè
  • ÄÏÏ - äîïóñòèìûé ïðåäåë ïîòðåáëåíèÿ
  • äð. — äðóãèå
  • ÄÒÏ — äîðîæíî-òðàíñïîðòíîå ïðîèñøåñòâèå
  • ÄÖÏ — äåòñêèé öåðåáðàëüíûé ïàðàëè÷
  • ÅÄ — åäèíèöà äåéñòâèÿ, åäèíèöà
  • ÆÂÏ — æåë÷åâûâîäÿùèå ïóòè
  • ÆÄÀ — æåëåçîäåôèöèòíàÿ àíåìèÿ
  • ÆÅË — æèçíåííàÿ åìêîñòü ëåãêèõ
  • ÆÊÁ — æåë÷åêàìåííàÿ áîëåçíü
  • ÆÊÊ — æåëóäî÷íî-êèøå÷íîå êðîâîòå÷åíèå
  • ÆÊÒ — æåëóäî÷íî-êèøå÷íûé òðàêò
  • ÆÍÂËÏ — æèçíåííî íåîáõîäèìûå è âàæíûå ëåêàðñòâåííûå ïðåïàðàòû (ñïèñîê, ïåðå÷åíü)
  • ÇÂÓÐ — çàäåðæêà âíóòðèóòðîáíîãî ðàçâèòèÿ
  • ÇË — çäîðîâûå ëþäè (ëèöà)
  • ÇÍÎ — çëîêà÷åñòâåííîå íîâîîáðàçîâàíèå
  • ÇÎ — çäðàâîîõðàíåíèå
  • ÇÎÆ — çäîðîâûé îáðàç æèçíè
  • ÇÑÍ — çàñòîéíàÿ ñåðäå÷íàÿ íåäîñòàòî÷íîñòü
  • èÀÏÔ — èíãèáèòîðû àíãèîòåíçèí-ïðåâðàùàþùåãî ôåðìåíòà
  • ÈÁÑ — èøåìè÷åñêàÿ áîëåçíü ñåðäöà
  • ÈÂË — èñêóññòâåííàÿ âåíòèëÿöèÿ ëåãêèõ
  • ÈÃÊÑ — èíãàëÿöèîííûå ãëþêîêîðòèêîñòåðîèäû
  • ÈÇË — èíòåðñòèöèàëüíûå çàáîëåâàíèÿ ëåãêèõ
  • ÈÊÏ — èììóíîêîìïðîìåòèðîâàííûå ïàöèåíòû
  • ÈË — èíòåðëåéêèí
  • ÈËÄÁ — èíòåãðèðîâàííîå ëå÷åíèå äåòñêèõ áîëåçíåé
  • ÈÌ — èíôàðêò ìèîêàðäà
  • ÈÌÀÎ — èíãèáèòîð(û) ìîíîàìèíîêñèäàçû
  • ÈÌáïÁÒ — èíôàðêò ìèîêàðäà áåç ïîäúåìà ñåãìåíòà ST
  • ÈÌÏ — èíôåêöèÿ ìî÷åâûõ (ìî÷åâûâîäÿùèõ) ïóòåé
  • ÈÌïÇÒ — èíôàðêò ìèîêàðäà ñ ïîäúåìîì ñåãìåíòà
  • ST ÈÌÒ — èíäåêñ ìàññû òåëà
  • ÈÎË — èíòðàîêóëÿðíàÿ ëèíçà
  • ÈÏÏ — èíãèáèòîðû ïðîòîííîé ïîìïû (ïðîòîííîãî íàñîñà)
  • ÈÏÏÏ — èíôåêöèè, ïåðåäàâàåìûå ïîëîâûì ïóòåì
  • ÈÑÑ — èíäèâèäóàëüíûå ñïàñàòåëüíûå ñðåäñòâà èñòîð. — èñòîðè÷åñêîå èòàë. — èòàëüÿíñêèé
  • ÈÒÏ — èäèîïàòè÷åñêàÿ òðîìáîöèòîïåíè÷åñêàÿ ïóðïóðà
  • ÈÒØ — èíôåêöèîííî-òîêñè÷åñêèé øîê ÈÔÀ — èììóíîôåðìåíòíûé àíàëèç
  • ÊÀ — êîðîíàðíàÿ(ûå) àðòåðèÿ(è)
  • ê — êèëîâîëüò
  • êã — êèëîãðàìì
  • ÊÄÁÀ — êîðîòêîäåéñòâóþùèå β2-àãîíèñòû
  • ÊÄÄ — êîíå÷íî-äèàñòîëè÷åñêîå äàâëåíèå
  • ÊÄÎ — êîíå÷íî-äèàñòîëè÷åñêèé îáúåì
  • ÊÄÐ — êîíå÷íî-äèàñòîëè÷åñêèé ðàçìåð
  • êèò. — êèòàéñêèé
  • êêàë — êèëîêàëîðèÿ
  • êë. — êëåòêè, êëåòîê
  • ÊÌÏ — êà÷åñòâî ìåäèöèíñêîé ïîìîùè
  • ÊîÀ — êîýíçèì À, êîôåðìåíò À
  • ÊÎÅ — êîëîíèåîáðàçóþùàÿ åäèíèöà
  • ÊÎÊ — êîìáèíèðîâàííûå îðàëüíûå êîíòðàöåïòèâû
  • ÊÏÒ — êîãíèòèâíî-ïîâåäåí÷åñêàÿ òåðàïèÿ
  • ÊÐ — êëèíè÷åñêèå ðåêîìåíäàöèè
  • ÊÑÄ — êîíå÷íî-ñèñòîëè÷åñêîå äàâëåíèå
  • ÊÑÎ — êîíå÷íî-ñèñòîëè÷åñêèé îáúåì
  • ÊÑÐ — êîíå÷íî-ñèñòîëè÷åñêèé ðàçìåð
  • ÊÒ — êîìïüþòåðíàÿ òîìîãðàôèÿ
  • ÊÒÂÐ — êîìïüþòåðíàÿ òîìîãðàôèÿ âûñîêîãî ðàçðåøåíèÿ
  • ÊÒÃ — êàðäèîòîêîãðàôèÿ
  • ÊÔÊ — êðåàòèíôîñôîêèíàçà
  • ÊÙÑ — êèñëîòíî-ùåëî÷íîå ñîñòîÿíèå
  • ë — ëèòð
  • ë/î — ëîæíîîòðèöàòåëüíûé
  • ë/ï — ëîæíîïîëîæèòåëüíûé
  • ËÀ — ëåãî÷íàÿ àðòåðèÿ
  • ëàò. — ëàòèíñêèé
  • ËÃ — ëþòåèíèçèðóþùèé ãîðìîí
  • ËÄÃ — ëàêòàòäåãèäðîãåíàçà
  • ËÆ — ëåâûé æåëóäî÷åê
  • ËÎÐ — èìåþùèé îòíîøåíèå ê îòîðèíîëàðèíãîëîãèè (ËÎÐ-âðà÷, ËÎÐ-îðãàíû)
  • ËÏ — ëåêàðñòâåííûé ïðåïàðàò
  • ËÏÂÏ — ëèïîïðîòåèíû âûñîêîé ïëîòíîñòè
  • ËÏÍÏ — ëèïîïðîòåèíû íèçêîé ïëîòíîñòè
  • ËÏÎÍÏ — ëèïîïðîòåèíû î÷åíü íèçêîé ïëîòíîñòè
  • ËÏÓ — ëå÷åáíî-ïðîôèëàêòè÷åñêîå ó÷ðåæäåíèå
  • ËÑ — ëåêàðñòâåííîå ñðåäñòâî
  • ËÓ — ëèìôàòè÷åñêèé óçåë, ëèìôîóçëû
  • ËÔÊ — ëå÷åáíàÿ ôèçêóëüòóðà
  • ì.á. — ìîæåò (ìîã, ìîãóò, ìîãëè) áûòü
  • Ì/Æ — ñîîòíîøåíèå ìóæ÷èí è æåíùèí
  • ìàêñÄ — ìàêñèìàëüíàÿ äîçà
  • ìàêñÍÄ — ìàêñèìàëüíàÿ íà÷àëüíàÿ äîçà
  • ìàêñÐÄ — ìàêñèìàëüíàÿ ðàçîâàÿ äîçà
  • ìàêñÑÄ — ìàêñèìàëüíàÿ ñóòî÷íàÿ äîçà
  • ÌÀÍÊ — ìåòîä àìïëèôèêàöèè íóêëåèíîâûõ êèñëîò
  • ÌÀÎ — ìîíîàìèíîêñèäàçà
  • ÌÂÏ — ìî÷åâûâîäÿùèå ïóòè ìã — ìèëëèãðàìì
  • ÌÄÁ — ìûøå÷íàÿ äèñòðîôèÿ Áåêêåðà
  • ÌÄÄ — ìûøå÷íàÿ äèñòðîôèÿ Äþøåííà
  • ÌÄÌÀ — ìåòèëåíäèîêñèìåòàìôåòàìèí
  • ME — ìåæäóíàðîäíàÿ åäèíèöà
  • ìåä. — ìåäèöèíñêèé
  • ìåñ — ìåñÿö
  • ÌÆ — ìîëî÷íàÿ æåëåçà
  • ÌÆÏ — ìåææåëóäî÷êîâàÿ ïåðåãîðîäêà
  • ÌÇ — ìèíèñòåðñòâî çäðàâîîõðàíåíèÿ
  • ìèí — ìèíóò(à)
  • ìèíÄ — ìèíèìàëüíàÿ äîçà
  • ìèíÑÄ — ìèíèìàëüíàÿ ñóòî÷íàÿ äîçà
  • ÌÊÁ — ìî÷åêàìåííàÿ áîëåçíü
  • ÌÊÁ-10 — Ìåæäóíàðîäíàÿ êëàññèôèêàöèÿ áîëåçíåé 10-ãî ïåðåñìîòðà
  • ÌÊÁ-11 — Ìåæäóíàðîäíàÿ êëàññèôèêàöèÿ áîëåçíåé 11-ãî ïåðåñìîòðà
  • ìê — ìèêðîâîëüò
  • ìêã — ìèêðîãðàìì
  • ÌÊÊ — ìàëûé êðóã êðîâîîáðàùåíèÿ
  • ìêë — ìèêðîëèòð
  • ìë — ìèëëèëèòð
  • ìëí — ìèëëèîí
  • ìëðä — ìèëëèàðä
  • ìì — ìèëëèìåòð
  • ìì ðò.ñò. — ìèëëèìåòð ðòóòíîãî ñòîëáà ììîëü — ìèëëèìîëü
  • ÌÍÍ — ìåæäóíàðîäíîå íåïàòåíòîâàííîå íàèìåíîâàíèå
  • ÌÍÎ — ìåæäóíàðîäíîå íîðìàëèçîâàííîå îòíîøåíèå
  • ÌÎ — ìåäèöèíñêàÿ îðãàíèçàöèÿ
  • ÌÏ — ìåäèöèíñêàÿ ïîìîùü
  • ÌÏÑ — ìî÷åïîëîâàÿ ñèñòåìà
  • ÌÐ — ìàãíèòíî-ðåçîíàíñíûé
  • ÌÐ-âåíîãðàôèÿ — ÌÐÒ âåí è ñèíóñîâ ãîëîâíîãî ìîçãà
  • ÌÐÒ — ìàãíèòíî-ðåçîíàíñíàÿ òîìîãðàôèÿ
  • ìñ — ìèëëèñåêóíäà
  • ÌÑÊÒ — ìóëüòèñïèðàëüíàÿ êîìïüþòåðíàÿ òîìîãðàôèÿ
  • ÌÑÝ — ìåäèêî-ñîöèàëüíàÿ ýêñïåðòèçà
  • ÌÒ — ìàññà òåëà
  • ìòÄÍÊ — ìèòîõîíäðèàëüíàÿ äåçîêñèðèáîíóêëåèíîâàÿ êèñëîòà
  • ÌÒÐ — ìàññà òåëà ïðè ðîæäåíèè
  • ÌÝ - ìèàëãè÷åñêèé ýíöåôàëîìèåëèò
  • í.ý. — íàøåé ýðû
  • ÍÀ — íåðâíàÿ àíîðåêñèÿ
  • ÍÀÄ — íèêîòèíàìèäàäåíèíäèíóêëåîòèä
  • ÍÀÄÍ — íèêîòèíàìèäàäåíèíäèíóêëåîòèä (âîññòàíîâëåííûé)
  • ÍÀÄÔ — íèêîòèíàìèäàäåíèíäèíóêëåîòèäôîñôàò
  • ÍÀÆÁÏ — íåàëêîãîëüíàÿ æèðîâàÿ áîëåçíü ïå÷åíè íàïð. — íàïðèìåð
  • ÍÁ — íåðâíàÿ áóëèìèÿ
  • ÍÄÎ — íåãàòèâíûé äåòñêèé îïûò
  • íåä — íåäåëè
  • íåì. — íåìåöêèé
  • íì — íàíîìåòð
  • ÍÌÈÖ — íàöèîíàëüíûé ìåäèöèíñêèé èññëåäîâàòåëüñêèé öåíòð
  • ÍÌÏ — íåîòëîæíàÿ (ìåäèöèíñêàÿ) ïîìîùü
  • ÍÌÒ — íèçêàÿ ìàññà òåëà
  • ÍÏÀ — íîðìàòèâíî-ïðàâîâîé àêò
  • ÍÏÂ — íèæíÿÿ ïîëàÿ âåíà
  • ÍÏÂÑ — íåñòåðîèäíûå ïðîòèâîâîñïàëèòåëüíûå ñðåäñòâà
  • ÍÑ — íåðâíàÿ ñèñòåìà
  • ÍÑÒ - íåñòðåññîâûé òåñò
  • ÍÐÏ — íîðìû ðàöèîíà ïèòàíèÿ
  • ÍÑÃ — íåéðîñîíîãðàôèÿ
  • ÍÝÊ — íåêðîòè÷åñêèé ýíòåðîêîëèò
  • ÍßÊ — íåñïåöèôè÷åñêèé ÿçâåííûé êîëèò
  • ÎÀÊ — îáùèé àíàëèç êðîâè
  • ÎÀÌ — îáùèé àíàëèç ìî÷è
  • ÎÀÏ — îòêðûòûé àðòåðèàëüíûé ïðîòîê
  • ÎÁÏ — îðãàíû áðþøíîé ïîëîñòè
  • ÎÃÁ — îñòðàÿ ãîðíàÿ áîëåçíü
  • ÎÃÌ — îòåê ãîëîâíîãî ìîçãà
  • ÎÄÍ — îñòðàÿ äûõàòåëüíàÿ íåäîñòàòî÷íîñòü
  • ÎÆÑÑ — îáùàÿ æåëåçîñâÿçûâàþùàÿ ñïîñîáíîñòü ñûâîðîòêè
  • ÎÇ — îðãàíèçàöèÿ çäðàâîîõðàíåíèÿ
  • îê. — îêîëî
  • ÎÊÐ — îáñåññèâíî-êîìïóëüñèâíîå ðàññòðîéñòâî
  • ÎÊÑ — îñòðûé êîðîíàðíûé ñèíäðîì
  • ÎËË — îñòðûé ëèìôîáëàñòíûé ëåéêîç
  • ÎÌÑ — îáÿçàòåëüíîå ìåäèöèíñêîå ñòðàõîâàíèå
  • ÎÌÒ — îðãàíû ìàëîãî òàçà
  • ÎÍÌÊ — îñòðîå íàðóøåíèå ìîçãîâîãî êðîâîîáðàùåíèÿ
  • ÎÍÌÏ — îòäåëåíèå íåîòëîæíîé (ìåäèöèíñêîé) ïîìîùè
  • ÎÍÌÒ — î÷åíü íèçêàÿ ìàññà òåëà
  • ÎÎÇ — îðãàíû (îðãàíèçàöèè/óïðàâëåíèÿ) çäðàâîîõðàíåíèÿ
  • ÎÎÍ — Îðãàíèçàöèÿ Îáúåäèíåííûõ Íàöèé
  • ÎÏÆ — îæèäàåìàÿ ïðîäîëæèòåëüíîñòü æèçíè
  • ÎÏÍ — îñòðàÿ ïî÷å÷íàÿ íåäîñòàòî÷íîñòü
  • ÎÏÑÑ - îáùåå ïåðèôåðè÷åñêîå ñîñóäèñòîå ñîïðîòèâëåíèå
  • ÎÐÂÈ — îñòðàÿ ðåñïèðàòîðíàÿ âèðóñíàÿ èíôåêöèÿ
  • ÎÐÄÑ — îñòðûé ðåñïèðàòîðíûé äèñòðåññ-ñèíäðîì
  • ÎÐÇ — îñòðîå ðåñïèðàòîðíîå çàáîëåâàíèå
  • ÎÐÈÒ — îòäåëåíèå ðåàíèìàöèè è èíòåíñèâíîé òåðàïèè (ICU)
  • ÎÑÂÎ — îáùåå ñîäåðæàíèå âîäû â îðãàíèçìå
  • ÎÔÂ — îáúåì ôîðñèðîâàííîãî âûäîõà
  • ÎÔÂ1 — îáúåì ôîðñèðîâàííîãî âûäîõà çà 1-þ ñåêóíäó
  • ÎÖÊ — îáúåì öèðêóëèðóþùåé êðîâè
  • ï.ç. — ïîëå çðåíèÿ (ìèêðîñêîïà)
  • ï/ê — ïîäêîæíî
  • ÏÀÂ — ïñèõîàêòèâíûå âåùåñòâà
  • ÏÂ — ïðîòðîìáèíîâîå âðåìÿ
  • ÏÂÊ — ïåðèôåðè÷åñêèé âåíîçíûé êàòåòåð
  • ÏÂË — ïåðèâåíòðèêóëÿðíàÿ ëåéêîìàëÿöèÿ
  • Ïã — ïðîñòàãëàíäèí
  • ÏÃÃ — ïðîãðàììà ãîñóäàðñòâåííûõ ãàðàíòèé îêàçàíèÿ ãðàæäàíàì ÐÔ áåñïëàòíîé ìåäèöèíñêîé ïîìîùè
  • ÏÄÊÂ — ïîëîæèòåëüíîå äàâëåíèå êîíöà âûäîõà (PEEP)
  • ÏÆ — ïðàâûé æåëóäî÷åê
  • ÏÆÆ — ïîäæåëóäî÷íàÿ æåëåçà
  • ÏÆÊ — ïîäêîæíî-æèðîâàÿ êëåò÷àòêà (ãèïîäåðìà)
  • ÏÊÀ — ïî÷å÷íûé êàíàëüöåâûé àöèäîç
  • ÏÊÌÄ — ïîÿñíî-êîíå÷íîñòíàÿ ìûøå÷íàÿ äèñòðîôèÿ
  • ÏËÑÃ — ïÿòíèñòàÿ ëèõîðàäêà Ñêàëèñòûõ ãîð
  • ÏÌÄÐ — ïðåäìåíñòðóàëüíîå äèñôîðè÷åñêîå ðàññòðîéñòâî
  • ÏÌÊ — ïðîëàïñ ìèòðàëüíîãî êëàïàíà
  • ÏÌÑ — ïðåäìåíñòðóàëüíûé ñèíäðîì
  • ÏÌÑÏ — ïåðâè÷íàÿ ìåäèêî-ñàíèòàðíàÿ ïîìîùü
  • ÏÍÆÊ — ïîëèíåíàñûùåííûå æèðíûå êèñëîòû
  • ÏÎÐÈÒ— ïåäèàòðè÷åñêîå îòäåëåíèå ðåàíèìàöèè è èíòåíñèâíîé òåðàïèè
  • ÏÎÒ — ïîñòóðàëüíàÿ îðòîñòàòè÷åñêàÿ òàõèêàðäèÿ
  • ÏÏÂ — ïíåâìîêîêêîâàÿ ïîëèñàõàðèäíàÿ âàêöèíà
  • ÏÏÎÀÊ — ïðÿìûå ïåðîðàëüíûå àíòèêîàãóëÿíòû
  • ÏÏÒ — ïëîùàäü ïîâåðõíîñòè òåëà
  • ÏÑÀ — ïðîñòàòîñïåöèôè÷åñêèé àíòèãåí
  • ÏÑÂ — ïèêîâàÿ ñêîðîñòü âûäîõà
  • ÏÑÂÕ — ïðîãðåññèðóþùèé ñåìåéíûé âíóòðèïå÷åíî÷-íûé õîëåñòàç
  • ÏÒ — ïñèõîòåðàïèÿ
  • ÏÒÂ — ïðîòðîìáèíîâîå âðåìÿ
  • ÏÒÃ — ïàðàòèðåîèäíûé ãîðìîí
  • ÏÒÈ — ïðîòðîìáèíîâûé èíäåêñ
  • ÏÒÑÐ — ïîñòòðàâìàòè÷åñêîå ñòðåññîâîå ðàññòðîéñòâî
  • ÏÔÝ — ïèùåâîé ôîëàòíûé ýêâèâàëåíò
  • ÏÖÐ — ïîëèìåðàçíàÿ öåïíàÿ ðåàêöèÿ
  • ÏØÃ — ïóðïóðà Øåíëåéíà-Ãåíîõà
  • ÏÙÆ — ïàðàùèòîâèäíûå æåëåçû
  • ÏÝÒ — ïîçèòðîííî-ýìèññèîííàÿ òîìîãðàôèÿ ð/ — ðàç â ... (ñ, ìèí, ÷, ñóò è ò.ï.)
  • ÐÀ — ðåâìàòîèäíûé àðòðèò
  • ÐÀÀÑ — ðåíèí-àíãèîòåíçèí-àëüäîñòåðîíîâàÿ ñèñòåìà ðàçã. — ðàçãîâîðíîå ðàçë. — ðàçëè÷íîå
  • ÐÀÑ — ðàññòðîéñòâî àóòèñòè÷åñêîãî ñïåêòðà
  • ÐÄÑ — ðåñïèðàòîðíûé äèñòðåññ-ñèíäðîì ðèì. — ðèìñêèé
  • ÐÈÔ — ðåàêöèÿ èììóíîôëþîðåñöåíöèè
  • ÐÊÈ — ðàíäîìèçèðîâàííûå êëèíè÷åñêèå èññëåäîâàíèÿ
  • ÐÊÌÏ — ðåñòðèêòèâíàÿ êàðäèîìèîïàòèÿ
  • ÐÈÃÀ — ðåàêöèÿ íåïðÿìîé ãåìàããëþòèíàöèè
  • ÐÍ - ðåòèíîïàòèÿ íåäîíîøåííûõ
  • ÐÍÊ — ðèáîíóêëåèíîâàÿ êèñëîòà
  • ÐÍÏ - ðåêîìåíäóåìóþ íîðìó ïîòðåáëåíèÿ
  • ÐÎÃÊ — ðåíòãåíîãðàôèÿ (ðåíòãåíîãðàììà) îðãàíîâ ãðóäíîé êëåòêè
  • ÐÎËÑÍÑ — ðåêîìåíäàöèè ïî îöåíêå è ëå÷åíèþ ïðè ñîðòèðîâêå â íåîòëîæíûõ ñèòóàöèÿõ
  • ÐÏÃÀ — ðåàêöèÿ ïðÿìîé ãåìàããëþòèíàöèè
  • ð-ð — ðàñòâîð
  • ð-ðèòåëü — ðàñòâîðèòåëü
  • ÐÐÊ — ðåöåïòîðû ðåòèíîåâîé êèñëîòû
  • PPM — ðàñøèðåííûå ðåàíèìàöèîííûå ìåðîïðèÿòèÿ
  • ÐÑÂ — ðåñïèðàòîðíî-ñèíöèòèàëüíûé âèðóñ
  • ÐÑÄ — ðàññòðîéñòâî ñòåðåîòèïíûõ äâèæåíèé
  • ÐÑÊ — ðåàêöèÿ ñâÿçûâàíèÿ êîìïëåìåíòà
  • ÐÑÏ - ðàñ÷åòíàÿ ñðåäíÿÿ ïîòðåáíîñòü
  • ÐÒÃÀ — ðåàêöèÿ òîðìîæåíèÿ ãåìàããëþòèíàöèè
  • ÐÒÍÃÀ — ðåàêöèÿ òîðìîæåíèÿ íåïðÿìîé ãåìàããëþòèíàöèè
  • ÐÔ — Ðîññèéñêàÿ Ôåäåðàöèÿ
  • ÐÕÐ — ðåòèíîåâûå Õ-ðåöåïòîðû
  • Ð×À — ðàäèî÷àñòîòíàÿ àáëÿöèÿ
  • ÐÝÑ — ðåòèêóëîýíäîòåëèàëüíàÿ ñèñòåìà
  • ñ — ñåêóíäà
  • ñâ-âî — ñâîéñòâî
  • ÑÀÌ - ñèíäðîì àñïèðàöèè ìåêîíèÿ
  • ÑÂÄÑ — ñèíäðîì âíåçàïíîé äåòñêîé ñìåðòè
  • ÑÃß — ñèíäðîì ãèïåðñòèìóëÿöèè ÿè÷íèêîâ
  • ÑÄ — ñàõàðíûé äèàáåò
  • ÑÄ-1 — ñàõàðíûé äèàáåò 1-ãî òèïà
  • ÑÄ-2 — ñàõàðíûé äèàáåò 2-ãî òèïà
  • ÑÄÂÃ — ñèíäðîì äåôèöèòà âíèìàíèÿ è ãèïåðàêòèâíîñòè
  • ÑÅ — ñóáúåäèíèöà
  • ÑÆÊ — ñâîáîäíûå æèðíûå êèñëîòû
  • ÑÇÄ - ñëóæáà çàùèòû äåòåé
  • ÑÇÑÒ — ñèñòåìíîå(ûå) çàáîëåâàíèå(ÿ) ñîåäèíèòåëüíîé òêàíè
  • ÑÈÇ — ñðåäñòâà èíäèâèäóàëüíîé çàùèòû
  • ÑÈÎÇÑ— ñåëåêòèâíûé èíãèáèòîð îáðàòíîãî çàõâàòà ñåðîòîíèíà
  • ÑÈÎÇÑÍ — ñåëåêòèâíûå èíãèáèòîðû îáðàòíîãî çàõâàòà ñåðîòîíèíà è íîðýïèíåôðèíà
  • ÑÊÀ — ñåðïîâèäíî-êëåòî÷íàÿ àíåìèÿ
  • ÑÊ — ñåðïîâèäíî-êëåòî÷íàÿ áîëåçíü
  • ÑÊ — ñèñòåìíàÿ êðàñíàÿ âîë÷àíêà
  • ÑÊÔ — ñêîðîñòü êëóáî÷êîâîé ôèëüòðàöèè
  • ÑËÐ — ñåðäå÷íî-ëåãî÷íàÿ ðåàíèìàöèÿ
  • ñì — ñàíòèìåòð
  • ñì âîä.ñò. — ñàíòèìåòð âîäÿíîãî ñòîëáà
  • ÑÌÆ — ñïèííîìîçãîâàÿ æèäêîñòü
  • ÑÌÈ — ñðåäñòâà ìàññîâîé èíôîðìàöèè
  • ÑÌÎ — ñòðàõîâàÿ ìåäèöèíñêàÿ îðãàíèçàöèÿ
  • ÑÌÏ — ñêîðàÿ ìåäèöèíñêàÿ ïîìîùü
  • ÑÌÝ — ñóäåáíî-ìåäèöèíñêàÿ ýêñïåðòèçà
  • ÑÍ — ñåðäå÷íàÿ íåäîñòàòî÷íîñòü
  • ÑÍÑÀÄÃ — ñèíäðîì íåàäåêâàòíîé ñåêðåöèè ÀÄÃ
  • ÑÎÀÑ — ñèíäðîì îáñòðóêòèâíîãî àïíîý ñíà (âî ñíå) ñîâð. — ñîâðåìåííûé
  • ÑÎÝ — ñêîðîñòü îñåäàíèÿ ýðèòðîöèòîâ
  • ÑÏÈÄ — ñèíäðîì ïðèîáðåòåííîãî èììóíîäåôèöèòà
  • ÑÏÊß — ñèíäðîì ïîëèêèñòîçíûõ ÿè÷íèêîâ
  • ÑÏÎÍ — ñèíäðîì ïîëèîðãàííîé íåäîñòàòî÷íîñòè
  • ÑÐÂ — Ñ-ðåàêòèâíûé áåëîê
  • ÑÐÊ — ñèíäðîì ðàçäðàæåííîãî êèøå÷íèêà
  • ÑðÑÄ — ñðåäíÿÿ ñóòî÷íàÿ äîçà
  • ÑÑÂ — ñèíäðîì Ñòåðäæà-Âåáåðà
  • ÑÑÂÐ — ñèíäðîì ñèñòåìíîé âîñïàëèòåëüíîé ðåàêöèè
  • ÑÑÇ — ñåðäå÷íî-ñîñóäèñòûå çàáîëåâàíèÿ
  • ÑÑÑ — ñåðäå÷íî-ñîñóäèñòàÿ ñèñòåìà
  • ÑÑÑÓ — ñèíäðîì ñëàáîñòè ñèíóñîâîãî óçëà
  • ÑÒ — Ñèíäðîì Òóðåòòà
  • ÑÒÃ — ñîìàòîòðîïíûé ãîðìîí
  • ÑÒÐ — ñòîéêîå (õðîíè÷åñêîå) ìîòîðíîå èëè âîêàëüíîå òèêîçíîå ðàññòðîéñòâî
  • ñóò — ñóòêè
  • ÑÕÓ — ñèíäðîì õðîíè÷åñêîé óñòàëîñòè
  • ò.ä. — òàê äàëåå
  • ò.å. — òî åñòü
  • ò.ê. — òàê êàê
  • ò.î. — òàêèì îáðàçîì
  • ò.ï. — òîìó ïîäîáíîå
  • Ò3 — òðèéîäòèðîíèí
  • Ò4 — òèðîêñèí
  • ÒÀÍÊ — òåñò àìïëèôèêàöèè íóêëåèíîâûõ êèñëîò
  • ÒÁÑ — òàçîáåäðåííûé ñóñòàâ
  • ÒÃÂ — òðîìáîç ãëóáîêèõ âåí
  • ÒÃÑÊ — òðàíñïëàíòàöèÿ ãåìîïîýòè÷åñêèõ ñòâîëîâûõ êëåòîê
  • ÒÈÀ — òðàíçèòîðíàÿ èøåìè÷åñêàÿ àòàêà
  • ÒÈÀÁ — òîíêîèãîëüíàÿ àñïèðàöèîííàÿ áèîïñèÿ
  • ÒÌÎ — òâåðäàÿ ìîçãîâàÿ îáîëî÷êà
  • TH — òîðãîâîå íàèìåíîâàíèå ëåêàðñòâåííûõ ñðåäñòâ
  • ÒÏÃÃ — òåððèòîðèàëüíàÿ ïðîãðàììà ãîñóäàðñòâåííûõ ãàðàíòèé îêàçàíèÿ ãðàæäàíàì ÐÔ áåñïëàòíîé ìåäèöèíñêîé ïîìîùè
  • ÒÏÌ — òðàâìàòè÷åñêîå ïîâðåæäåíèå ìîçãà
  • ÒÒ — òåìïåðàòóðà òåëà
  • ÒÒÃ — òèðåîòðîïíûé ãîðìîí
  • ÒÔÐ — òðàíñôîðìèðóþùèé ôàêòîð ðîñòà
  • ÒÖÀ — òðèöèêëè÷åñêèå àíòèäåïðåññàíòû
  • òûñ. — òûñÿ÷à
  • ÒÝÄ —òðàíçèòîðíàÿ ýðèòðîáëàñòîïåíèÿ äåòñêîãî âîçðàñòà
  • ÒÝËÀ — òðîìáîýìáîëèÿ ëåãî÷íîé àðòåðèè
  • ÒÝÎ — òðîìáîýìáîëè÷åñêèå îñëîæíåíèÿ
  • ÓÇÄÑ — óëüòðàçâóêîâîå äóïëåêñíîå ñêàíèðîâàíèå
  • ÓÇÈ — óëüòðàçâóêîâîå èññëåäîâàíèå
  • óñòàð. — óñòàðåâøåå
  • ÓÔ — óëüòðàôèîëåòîâûé
  • ÓÔÎ — óëüòðàôèîëåòîâîå îáëó÷åíèå
  • ÔÀÏ — ôåëüäøåðñêî-àêóøåðñêèé ïóíêò
  • ÔÂ — ôðàêöèÿ âûáðîñà
  • ÔÂÄ — ôóíêöèè âíåøíåãî äûõàíèÿ
  • ÔÆÅË — ôîðñèðîâàííàÿ æèçíåííàÿ åìêîñòü ëåãêèõ
  • ÔÇ — Ôåäåðàëüíûé çàêîí
  • ôèçèîë. — ôèçèîëîãè÷åñêèé
  • ÔÊ — ôóíêöèîíàëüíûé êëàññ
  • ÔÊÑ — ôèáðîêîëîíîñêîïèÿ
  • ÔÊÓ — ôåíèëêåòîíóðèÿ
  • ÔÍ — ôèçè÷åñêàÿ íàãðóçêà
  • ÔÈÎ — ôàêòîð íåêðîçà îïóõîëè
  • ÔÎÌÑ — ôåäåðàëüíûé ôîíä îáÿçàòåëüíîãî ìåäèöèíñêîãî ñòðàõîâàíèÿ
  • ÔÎÑ — ôîñôîðîðãàíè÷åñêèå ñîåäèíåíèÿ
  • ÔÏ — ôèáðèëëÿöèÿ ïðåäñåðäèé
  • ôð. — ôðàíöóçñêèé
  • ÔÑÃ — ôîëëèêóëîñòèìóëèðóþùèé ãîðìîí
  • ÔÝÃÄÑ — ôèáðîýçîôàãîãàñòðîäóîäåíîñêîïèÿ
  • ÕÁÏ — õðîíè÷åñêàÿ áîëåçíü ïî÷åê
  • ÕÃ× — õîðèîíè÷åñêèé ãîíàäîòðîïèí ÷åëîâåêà
  • ÕÄÍ — õðîíè÷åñêàÿ äûõàòåëüíàÿ íåäîñòàòî÷íîñòü
  • õèì. — õèìè÷åñêàÿ
  • ÕÍÇË —õðîíè÷åñêèå íåñïåöèôè÷åñêèå çàáîëåâàíèÿ ëåãêèõ
  • ÕÎÁË — õðîíè÷åñêàÿ îáñòðóêòèâíàÿ áîëåçíü ëåãêèõ
  • ÕÏÍ — õðîíè÷åñêàÿ ïî÷å÷íàÿ íåäîñòàòî÷íîñòü
  • ÕÑ — õîëåñòåðèí
  • ÕÑÍ — õðîíè÷åñêàÿ ñåðäå÷íàÿ íåäîñòàòî÷íîñòü
  • XT — õèìèîòåðàïèÿ
  • ÖÂÄ — öåíòðàëüíîå âåíîçíîå äàâëåíèå
  • ÖÂÊ — öåíòðàëüíûé âåíîçíûé êàòåòåð
  • ÖÈÊ — öèðêóëèðóþùèå èììóííûå êîìïëåêñû
  • ÖÌÂ — öèòîìåãàëîâèðóñ
  • ÖÍÑ — öåíòðàëüíàÿ íåðâíàÿ ñèñòåìà
  • ÖÎÃ — öèêëîîêñèãåíàçà
  • ÖÏÄ — öåðåáðàëüíîå ïåðôóçèîííîå äàâëåíèå
  • ÖÑÒÑ — öåðåáðàëüíûé ñîëüòåðÿþùèé ñèíäðîì ÷ — ÷àñ
  • ×Ä — ÷àñòîòà äûõàíèÿ
  • ×ÄÄ — ÷àñòîòà äûõàòåëüíûõ äâèæåíèé
  • ×Ê — ÷ðåñêîæíîå êîðîíàðíîå âìåøàòåëüñòâî
  • ×ÌÍ — ÷åðåïíî-ìîçãîâûå íåðâû
  • ×ÌÒ — ÷åðåïíî-ìîçãîâàÿ òðàâìà
  • ×Í — ÷åðåïíûå íåðâû
  • ×Ñ — ÷óâñòâèòåëüíîñòü/ñïåöèôè÷íîñòü (×Ñ 97%/87%)
  • ×ÑÑ — ÷àñòîòà ñåðäå÷íûõ ñîêðàùåíèé
  • ×ÑÑÏ - ÷àñòîòà ñåðäå÷íûõ ñîêðàùåíèé ïëîäà
  • ×Ò — ÷àñòè÷íîå òðîìáîïëàñòèíîâîå âðåìÿ
  • ØÊÃ — øêàëà êîìû Ãëàçãî
  • ØÎÏ — øåéíûé îòäåë ïîçâîíî÷íèêà
  • ÙÆ — ùèòîâèäíàÿ æåëåçà
  • ÃÖÔ — ùåëî÷íàÿ ôîñôàòàçà
  • ÝÀÐ — ýêâèâàëåíò àêòèâíîñòè ðåòèíîëà
  • ÝÄÒÀ — ýòèëåíäèàìèíòåòðàóêñóñíàÿ êèñëîòà (ýòèëåíäèàìèíòåòðààöåòàò)
  • ÝÊÃ — ýëåêòðîêàðäèîãðàôèÿ
  • ÝÊÌÎ — ýêñòðàêîðïîðàëüíàÿ ìåìáðàííàÿ îêñèãåíàöèÿ
  • ÝÊÎ — ýêñòðàêîðïîðàëüíîå îïëîäîòâîðåíèå
  • ÝÊÑ — ýëåêòðîêàðäèîñòèìóëÿòîð, ýëåêãðîêàðäèîñòèìóëÿöèÿ
  • ÝÌÃ — ýëåêòðîìèîãðàôèÿ
  • ÝÌÊ — ýëåêòðîííàÿ ìåäèöèíñêàÿ êàðòà
  • ÝÌÏ — ýêñòðåííàÿ ìåäèöèíñêàÿ ïîìîùü
  • ÝÍÌÏ — ýêñòðåííàÿ è íåîòëîæíàÿ ìåäèöèíñêàÿ ïîìîùü
  • ÝÍÌÒ — ýêñòðåìàëüíî íèçêàÿ ìàññà òåëà
  • ÝÒÒ — ýíäîòðàõåàëüíàÿ òðóáêà
  • ÝõîÊà — ýõîêàðäèîãðàôèÿ
  • ÝÝÃ — ýëåêòðîýíöåôàëîãðàôèÿ
  • ÞÄÌ — þâåíèëüíûé äåðìàòîìèîçèò
  • ÞÈÀ — þâåíèëüíûé èäèîïàòè÷åñêèé àðòðèò
  • ßÁ — ÿçâåííàÿ áîëåçíü
  • ÀÀ — àìèëîèä A (amyloid À)
  • ÀÀÐ — Àìåðèêàíñêàÿ àêàäåìèÿ ïåäèàòðèè (American Academy of Pediatrics)
  • ABC — àëãîðèòì íåîòëîæíîé ïîìîùè «äûõàòåëüíûå ïóòè-äûõàíèå-êðîâîîáðàùåíèå» (Airways-Breathing-Circulation)
  • ÀÂÑÀ3 — áåëêîâûé ÷ëåí ÀÒÔ-ñâÿçûâàþùåé êàññåòû À3
  • ÀÂÑÂ11— ãåí ÀÒÔ-ñâÿçûâàþùåé êàññåòû, 11-é ÷ëåí ïîäñåìåéñòâà  (ATP-binding cassette, sub-family  member 11)
  • ÀÂÑÂ4 — ãåí ÀÒÔ-ñâÿçûâàþùåé êàññåòû, 4-é ÷ëåí ïîäñåìåéñòâà  (ATP-binding cassette 4 gene)
  • ÀÂÑÑ2 — ãåí, êîäèðóþùèé 2-é ÷ëåí ïîäñåìåéñòâà Ñ ÀÒÔ-ñâÿçûâàþùèõ êàññåò (ATP-binding cassette sub-family Ñ member 2)
  • ABCDE — àëãîðèòì íåîòëîæíîé ïîìîùè «äûõàòåëüíûå ïóòè-äûõàíèå-êðîâîîáðàùåíèå-íåâðîëîãè÷åñêèé ñòàòóñ-âíåøíèé âèä» (Airways-Breathing-Circulation-Disability- Exposure)
  • ABCG5/G8 — ãåòåðîäèìåð ïåðåíîñ÷èêà ÀÒÔ-ñâÿçûâàþùåé êàññåòû ABCG5 è ABCG8 (The heterodimer of ATP-binding cassette transporter ABCG5 and ABCG8)
  • AC — äî åäû (ïðè íàçíà÷åíèÿõ) — ante cibum
  • ÀÑÅÐ — Àìåðèêàíñêàÿ êîëëåãèÿ âðà÷åé íåîòëîæíîé ïîìîùè (American College of Emergency Physicians)
  • ACOG — Àìåðèêàíñêàÿ êîëëåãèÿ àêóøåðîâ è ãèíåêîëîãîâ (American College of Obstetricians and Gynecologists)
  • AHA — Àìåðèêàíñêàÿ êàðäèîëîãè÷åñêàÿ àññîöèàöèÿ (American Heart Association)
  • ALTE — î÷åâèäíîå îïàñíîå äëÿ æèçíè ñîáûòèå (apparent life-threatening event)
  • APLS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè, ñïîíñèðóåìûå Àìåðèêàíñêîé àêàäåìèåé ïåäèàòðèè è Àìåðèêàíñêîé êîëëåãèåé âðà÷åé íåîòëîæíîé ïîìîùè (Advanced Pediatric Life Support)
  • ARPKD — àóòîñîìíî-ðåöåññèâíûé ïîëèêèñòîç ïî÷åê
  • ASCVD-ðèñê — ðèñê ðàçâèòèÿ àòåðîñêëåðîòè÷åñêîãî ñåðäå÷íî-ñîñóäèñòîãî çàáîëåâàíèÿ (ArterioSclerotic Cardiovascular Disease, ASCVD)
  • AVPU — øêàëà äëÿ îöåíêè óðîâíÿ ñîçíàíèÿ («â ÿñíîì ñîçíàíèè»; «ðåàêöèÿ íà âåðáàëüíûå ðàçäðàæèòåëè»; «ðåàêöèÿ íà áîëü»; «áåç ñîçíàíèÿ») (alert, verbal, pain, unresponsive)
  • BCS — ìèòîõîíäðèàëüíûé øàïåðîí BCS1 (mitochondrial chaperone BCS1)
  • BIN — áèíîìèíàëüíàÿ íîìåíêëàòóðà «æèâîé» ïðèðîäû
  • BiPAP — ðåæèì èñêóññòâåííîé âåíòèëÿöèè ëåãêèõ ñ äâóìÿ óðîâíÿìè ïîëîæèòåëüíîãî äàâëåíèÿ (bilevel positive airway pressure) = ÂÐÀÐ
  • BNP — íàòðèéóðåòè÷åñêèé ïåïòèä Â-òèïà — ìîçãîâîé ( (brain)-type natriuretic peptide)
  • BRUE — áûñòðî ðàçðåøèâøèåñÿ íåîáúÿñíèìûå ñîáûòèÿ (Brief resolved unexplained events)
  • BSEP — íàñîñ âûâåäåíèÿ ñîëåé æåë÷íûõ êèñëîò
  • CADASIL — öåðåáðàëüíàÿ àóòîñîìíî-äîìèíàíòíàÿ àðòåðèîïàòèÿ ñ ïîäêîðêîâûìè èíôàðêòàìè è ëåéêîýíöåôàëîïàòèåé (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
  • CAPS — êðèîïèðèí-àññîöèèðîâàííûé ïåðèîäè÷åñêèé ñèíäðîì (cryopyrin-associated periodic syndrome)
  • CBIT — êîìïëåêñíîå ïîâåäåí÷åñêîå âîçäåéñòâèå ïðè òèêàõ (Comprehensive behavioral intervention for tics)
  • CD — êëàñòåðû äèôôåðåíöèðîâêè (clusters of differentiation)
  • CDC — Öåíòð ïî êîíòðîëþ è ïðîôèëàêòèêå çàáîëåâàíèé, ÑØÀ (Center for Disease Control and Prevention)
  • CDG — âðîæäåííûå íàðóøåíèÿ ãëèêîçèëèðîâàíèÿ (Congenital Disorder of Glycosylation)
  • CFTR — òðàíñìåìáðàííûé ðåãóëÿòîð ìóêîâèñöèäîçà (cystic fibrosis transmembrane regulator)
  • CH — ãåìîëèòè÷åñêèé êîìïëåìåíò (hemolytic complement)
  • CLLS — øêàëà îöåíêè îñòðîé ãîðíîé áîëåçíè îçåðà Ëóèç ó äåòåé (Childrens Lake Louise Score)
  • CMT — Øàðêî-Ìàðè-Òóòà áîëåçíü (Charcot-Marie-Tooth disease)
  • ÑÐÀÐ — ïîñòîÿííîå ïîëîæèòåëüíîå äàâëåíèå â äûõàòåëüíûõ ïóòÿõ (Constant Positive Airway Pressure)
  • CYP — öèòîõðîì îáùèé
  • DAF — ôàêòîð óñêîðåíèÿ ðàñïàäà (decay-accelerating factor)
  • DGAT1 —äèàöèëãëèöåðèí-1-àöèëòðàíñôåðàçà (diacylglycerol acyltransferase 1)
  • DHR — äèãèäðîðîäàìèí (dihydrorhodamine)
  • DSM — Äèàãíîñòè÷åñêîå è ñòàòèñòè÷åñêîå ðóêîâîäñòâî ïî ïñèõè÷åñêèì ðàññòðîéñòâàì (Diagnostic and Statistical Manual of Mental Disorders)
  • EAST syndrome — ýïèëåïñèÿ, àòàêñèÿ, ñåíñîíåâðàëüíàÿ òóãîóõîñòü è òóáóëîïàòèÿ (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
  • EBM — äîêàçàòåëüíàÿ ìåäèöèíà (Evidence based medicine)
  • EPCAM— ìîëåêóëà àäãåçèè ýïèòåëèàëüíûõ êëåòîê (epithelial cell adhesion molecule)
  • ESC — Åâðîïåéñêîå îáùåñòâî êàðäèîëîãèè (European Society of Cardiology)
  • EXIT — ëå÷åíèå âíå ìàòêè âî âðåìÿ ðîäîâ (Ex utero intrapartum treatment)
  • FAST — ñôîêóñèðîâàííàÿ ñîíîãðàôèÿ áðþøíîé ïîëîñòè ïðè òðàâìå (focused assessment with sonography in trauma)
  • FDA — Êîìèòåò ïî êîíòðîëþ çà ëåêàðñòâåííûìè âåùåñòâàìè è ïèùåâûìè äîáàâêàìè, ÑØÀ (Food and Drug Administration)
  • FFR — ôðàêöèîííûé ðåçåðâ êðîâîòîêà (Fractional Flow Reserve)
  • FGF-23 — ôàêòîð ðîñòà ôèáðîáëàñòîâ-23 (Fibroblast growth factor-23)
  • FIC 1 —ñåìåéíûé âíóòðèïå÷åíî÷íûé õîëåñòàç 1-ãî òèïà, áîëåçíü Áàéëåðà (familial intrahepatic cholestasis)
  • FiO2 — ôðàêöèÿ êèñëîðîäà (âî âäûõàåìîì âîçäóõå, ãàçîâîé ñìåñè)
  • FISH — ôëóîðåñöåíòíàÿ in situ ãèáðèäèçàöèÿ (fluorescence in situ hybridization)
  • FLAIR — âîññòàíîâëåíèå èíâåðñèè ñ îñëàáëåíèåì æèäêîñòè (fluid-attenuated inversion recovery)
  • FMF — ñåìåéíàÿ ñðåäèçåìíîìîðñêàÿ ëèõîðàäêà (Familial Mediterranean fever)
  • GATA — gata-ñâÿçûâàþùèé áåëîê
  • HADH — ãèäðîêñèëàöèë-ÊîÀ-äåãèäðîãåíàçà (Hydro-xyacyl-Coenzyme A dehydrogenase)
  • HAV — âèðóñ ãåïàòèòà Â (hepatitis A virus)
  • Hb — ãåìîãëîáèí
  • HBcAg — ñåðäöåâèííûé àíòèãåí âèðóñà ãåïàòèòà Â
  • HBeAg — àíòèãåí âèðóñà ãåïàòèòà Â
  • HBsAg — ïîâåðõíîñòíûé àíòèãåí âèðóñà ãåïàòèòà Â
  • HBV — âèðóñ ãåïàòèòà  (hepatitis  virus)
  • HCV — âèðóñ ãåïàòèòà Ñ (hepatitis Ñ virus)
  • HDV — âèðóñ ãåïàòèòà D (hepatitis D virus)
  • HFNC — íàçàëüíûå êàíþëè âûñîêîãî ïîòîêà (heated, high-flow nasal cannula)
  • Hib — ãåìîôèëüíàÿ ïàëî÷êà òèïà  (Haemophilus influenzae  type)
  • HLA — ëåéêîöèòàðíûå àíòèãåíû (ãëàâíîãî êîìïëåêñà ãèñòîñîâìåñòèìîñòè) ÷åëîâåêà (human leukocyte antigens)
  • HR — îòíîøåíèå ðèñêîâ (hazard ratio)
  • HRT — òåðàïèÿ îòìåíû ïðèâû÷êè (Habit reversal therapy)
  • Ht — ãåìàòîêðèò
  • HTLV — Ò-ëèìôîòðîïíûé âèðóñ ÷åëîâåêà (human T-lymphotropic virus)
  • Ig — èììóíîãëîáóëèí
  • IgA — èììóíîãëîáóëèí A
  • IgE — èììóíîãëîáóëèí E
  • IgG — èììóíîãëîáóëèí G
  • IgM — èììóíîãëîáóëèí M
  • IL — èíòåðëåéêèí
  • IPEX — Õ-ñöåïëåííûé ñèíäðîì èììóííîé äèñðå-ãóëÿöèè, ïîëèýíäîêðèíîïàòèè è ýíòåðîïàòèè (Immunedysregulation polyendocrinopathy enteropathy, X-linked)
  • IQ — êîýôôèöèåíò óìñòâåííîãî ðàçâèòèÿ (intelligence quotient)
  • JAK — ÿíóñ-êèíàçà (Janus kinase)
  • LFA — àíòèãåí, àêòèâèðóþùèé ôóíêöèþ ëåéêîöèòîâ (Lymphocyte function-associated antigen)
  • LT — ëåéêîòðèåí
  • MALT — ëèìôîèäíàÿ òêàíü ñëèçèñòîé îáîëî÷êè (mucosa-associated lymphoid tissue)
  • MASP — ÌÑË-àññîöèèðîâàííàÿ ñåðèíîâàÿ ïðîòåàçà (MBL-associated serine protease)
  • MBL — ìàííîçî-ñâÿçûâàþùèé ëåêòèí (mannose-
  • binding lectin)
  • MCP — ìåìáðàííûé áåëîê-êîôàêòîð (membrane cofactor protein)
  • MDR3 — áåëîê ìíîæåñòâåííîé ëåêàðñòâåííîé óñòîé÷èâîñòè 3 (multidrug resistance protein 3)
  • MELAS — ìèòîõîíäðèàëüíàÿ ýíöåôàëîïàòèÿ, ëàêòîàöèäîç è èíñóëüòîïîäîáíûå ýïèçîäû (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
  • MERRF — ìèîêëîíè÷åñêàÿ ýïèëåïñèÿ ñ ðâàíûìè êðàñíûìè âîëîêíàìè (Myoclonic epilepsy with ragged red fibers)
  • Mr — êàæóùàÿñÿ ìîëåêóëÿðíàÿ ìàññà
  • MRP — áåëîê ñ ìíîæåñòâåííîé ëåêàðñòâåííîé óñòîé÷èâîñòüþ (multidrug-resistant protein)
  • MRSA — ìåòèöèëëèíðåçèñòåíòíûé çîëîòèñòûé ñòàôèëîêîêê
  • MSSA — ìåòèöèëëèí÷óâñòâèòåëüíûé çîëîòèñòûé ñòàôèëîêîêê
  • NB! — âàæíî, îáðàòèòü âíèìàíèå (Nota bene)
  • NICE — Íàöèîíàëüíûé èíñòèòóò çäîðîâüÿ è êëèíè÷åñêîãî ñîâåðøåíñòâîâàíèÿ (êà÷åñòâà ìåäèöèíñêîé ïîìîùè) Âåëèêîáðèòàíèè (National Institute for Health and Clinical Excellence)
  • NK — åñòåñòâåííûå êëåòêè-êèëëåðû (natural killer)
  • NMDA — N-ìåòèë-D-àñïàðòàò (N-methyl-D-aspartate)
  • NMDA — N-ìåòèë-D-àñïàðòàòíûå ðåöåïòîðû
  • NNT — ÷èñëî áîëüíûõ, êîòîðûõ íåîáõîäèìî ïðîëå÷èòü, ÷òîáû äîñòè÷ü êàêîãî-òî óêàçàííîãî ýôôåêòà (Number Need to Treatment)
  • OR — îòíîøåíèå øàíñîâ (odds ratio)
  • paCO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà â àðòåðèàëüíîé êðîâè
  • PALS — êóðñû ðàñøèðåííûõ ðåàíèìàöèîííûõ ìåðîïðèÿòèé â ïåäèàòðèè (Pediatric Advanced Life Support)
  • PANDAS — àóòîèììóííîå íåéðîïñèõèàòðè÷åñêîå ðàññòðîéñòâî â äåòñêîì âîçðàñòå, àññîöèèðîâàííîå ñî ñòðåïòîêîêêîâîé èíôåêöèåé (Pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
  • PANS — îñòðûé íåéðîïñèõèàòðè÷åñêèé ñèíäðîì â äåòñêîì âîçðàñòå (Pediatric acute-onset neuropsychiatric syndrome)
  • paO2 — ïàðöèàëüíîå äàâëåíèå êèñëîðîäà â àðòåðèàëüíîé êðîâè
  • PAS — ôóêñèíñåðíèñòàÿ êèñëîòà, ðåàêòèâ Øèôôà (periodic acid-Shiff)
  • PC — ïîñëå åäû (ïðè íàçíà÷åíèÿõ) — post cibum ðÑO2 — ïàðöèàëüíîå äàâëåíèå óãëåêèñëîãî ãàçà
  • PCSK-9 — ïðîïðîòåèíîâàÿ êîíâåðòàçà ñóáòèëèçèí-êåêñè-íîâîãî òèïà 9 (proprotein convertase subtilisin/ kexin type 9)
  • PFAPA — ïåðèîäè÷åñêàÿ ëèõîðàäêà ñ àôòîçíûì ñòîìàòèòîì, ôàðèíãèòîì è ëèìôàäåíèòîì (Periodic Fevers with Aphthous stomatitis, Pharyngitis and Adenitis)
  • PFIC — ñåìåéíûé âíóòðèïå÷åíî÷íûé õîëåñòàç (familial intrahepatic cholestasis)
  • Pg — ïðîñòàãëàíäèí
  • pH — âîäîðîäíûé ïîêàçàòåëü
  • PIM — ïîêàçàòåëü ëåòàëüíîãî èñõîäà ó äåòåé (Pediatric Index of Mortality)
  • piO2 — ïàðöèàëüíîå äàâëåíèå êèñëîðîäà âî âäûõàåìîì
  • âîçäóõå
  • ðO2 — ïàðöèàëüíîå äàâëåíèå êèñëîðîäà
  • POLG — ñóáúåäèíèöà ÄÍÊ-ïîëèìåðàçû ó
  • PRISA II — îöåíêà ðèñêà ãîñïèòàëèçàöèè ó äåòåé II (Pediatric Risk of Admission)
  • PRISM — ðèñê ëåòàëüíîãî èñõîäà ó äåòåé (Pediatric Risk of Mortality)
  • PRN — ïðè (ïî) íåîáõîäèìîñòè (Pro re nata — ïðè âîçíèêíîâåíèè îáñòîÿòåëüñòâ)
  • PRSS — ãåí ñåðèíîâîé ïðîòåàçû
  • PS. — ïðèìå÷àíèå (Post scriptum)
  • PUVA-òåðàïèÿ — ïñîðàëåí-óëüòðàôèîëåò À-òåðàïèÿ (psoralen and ultraviolet À)
  • Q#H — êàæäûå # ÷àñîâ (ïðè íàçíà÷åíèÿõ) — quaque ... hora
  • QAM — êàæäîå óòðî (ïðè íàçíà÷åíèÿõ) — quaque ante meridiem
  • QPM — êàæäûé âå÷åð (ïðè íàçíà÷åíèÿõ) — quaque post meridiem
  • RAG — ãåí, àêòèâèðóþùèé ðåêîìáèíàçó
  • RePEAT— ïåðåñìîòðåííûé èíñòðóìåíò äëÿ îöåíêè ïåäèàòðè÷åñêîé íåîòëîæíîé ìåäèöèíñêîé ïîìîùè (Revised Pediatric Emergency Assessment Tool)
  • RF — ðåâìàòîèäíûé ôàêòîð
  • Rh — ðåçóñ(-ôàêòîð)
  • Rh«-» — ðåçóñ-îòðèöàòåëüí(ûé)
  • Rh«+» — ðåçóñ-ïîëîæèòåëüí(ûé)
  • ROHHAD — áûñòðî ðàçâèâàþùååñÿ îæèðåíèå ñ äèñôóíêöèåé ãèïîòàëàìóñà, ãèïîâåíòèëÿöèåé è ñïîíòàííîé äèñðåãóëÿöèåé (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
  • RR — îòíîñèòåëüíûé ðèñê (relative risk èëè risk ratio) RW — ðåàêöèÿ Âàññåðìàíà (reaction of Wassermann)
  • SaO2 — ñàòóðàöèÿ àðòåðèàëüíîé êðîâè êèñëîðîäîì SatO2 — íàñûùåíèå êðîâè êèñëîðîäîì
  • ScvO2 — íàñûùåíèå êèñëîðîäîì öåíòðàëüíîé âåíîçíîé êðîâè (Central venous oxygen saturation)
  • SD — ñòàíäàðòíîå îòêëîíåíèå (standart deviation) SFTPA — ãåí ñóðôàêòàíòíîãî áåëêà A
  • SFTPB — ãåí ñóðôàêòàíòíîãî áåëêà Â
  • SFTPC — ãåí ñóðôàêòàíòíîãî áåëêà Ñ
  • SPINK — èíãèáèòîð ñåðèíîâîé ïðîòåàçû
  • SpO2 — íàñûùåíèå (ñàòóðàöèÿ) ãåìîãëîáèíà êèñëîðîäîì spp. — âèäû (ïðè ðîäîâîì èìåíè ìèêðîîðãàíèçìîâ)
  • Src. — èñòî÷íèê èíôîðìàöèè, áèáëèîãðàôè÷åñêàÿ ññûëêà (source)
  • STAT1 — ñèãíàëüíûé ïðåîáðàçîâàòåëü è àêòèâàòîð òðàíñêðèïöèè 1 (signal transducer and activator of transcription)
  • TA — ìåæäóíàðîäíàÿ àíàòîìè÷åñêàÿ òåðìèíîëîãèÿ TCR — T-êëåòî÷íûé ðåöåïòîð (T-cell receptor)
  • TLRs — Òîëë-ïîäîáíûå ðåöåïòîðû (Toll-like receptors) TNF — ôàêòîð íåêðîçà îïóõîëè (tumor necrosis factor)
  • TORCH — òîêñîïëàçìîç, êðàñíóõà, öèòîìåãàëîâèðóñíàÿ èíôåêöèÿ, ãåðïåñ è äðóãèå èíôåêöèè (Toxoplasmosis, Other infections, Rubella, Cytomegalovirus Herpes simplex)
  • TPM — ìóòàöèÿ òðîïîìèîçèíà (mutation of the tropomyosin)
  • TRAP — ñèíäðîì îáðàòíîé àðòåðèàëüíîé ïåðôóçèè áëèçíåöîâ (twin reversed arterial perfusion)
  • TRAPS — ïåðèîäè÷åñêèé ñèíäðîì, àññîöèèðîâàííûé ñ ðåöåïòîðîì ôàêòîðà íåêðîçà îïóõîëè (Tumor Necrosis Factor Receptor-Associated Periodic Syndrome)
  • ™ — òîðãîâàÿ ìàðêà
  • URL — èíòåðíåò-ññûëêà, àäðåñ èíòåðíåò-ðåñóðñà (Uniform Resource Locator)
  • VEGF — ôàêòîð ðîñòà ýíäîòåëèÿ ñîñóäîâ (Vascular Endothelial Growth Factor)
  • WPW — ñèíäðîì Âîëüôà-Ïàðêèíñîíà-Óàéòà (Wolff-Parkinson-White)
  • XLA — Õ-ñöåïëåííàÿ àãàììàãëîáóëèíåìèÿ (X-linked agammaglobulinemia)
  • aDG-RD — äèñòðîôèè, ñâÿçàííûå ñ a-äèñòðîãëèêàíàìè (alpha dystroglycan-related dystrophies)
  • β-ÕÃ× — β-ñóáúåäèíèöà õîðèîíè÷åñêîãî ãîíàäîòðîïèíà ÷åëîâåêà

 õîäå ïîäãîòîâêè ñòàòåé ïî äåòñêîé ýêîëîãèè â ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà ÌåäÓíèâåð èñïîëüçîâàíû òðóäû ñëåäóþùèõ àâòîðîâ:

  1. American Academy of Pediatrics Committee on Environmental Health: In Etzel RA, editor: Pediatric environmental health, ed 3, Elk Grove Village, IL, 2012, American Academy of Pediatrics.
  2. American Medical Association, American Nurses Association—American Nurses Foundation, Centers for Disease Control and Prevention, et al: Diagnosis and management of foodborne illnesses: a primer for physicians and other health care professionals, Chicago, 2004, AMA.
  3. Bhat RV, Beedu SR, Ramakrishna Y, Munshi KL: Outbreak of trichothecene mycotoxicosis associated with consumption of mould-damaged wheat products in Kashmir Valley, India, Lancet 1(8628):35–37, 1989.
  4. Bhat RV, Prathaphumar HS, Rao PA, Rao VS: A foodborne disease outbreak due to the consumption of moldy sorghum and maize containing fumonisin mycotoxins, Clin Toxicol 35:249–255, 1997.
  5. Croft WA, Jarvis BB, Yatawara CS: Airborne outbreak of trichothecene toxicosis, Atmos Environ 20:549–552, 1986.
  6. Dooyema CA, Neri A, Lo Y-C, et al: Outbreak of fatal childhood lead poisoning related to artisanal gold mining in northwestern Nigeria, 2010, Environ Health Perspect 120:601–607, 2012.
  7. Easterling DR, Meehl GA, Parmesan C, et al: Climate extremes: observations, modeling, and impacts, Science 289:2068–2074, 2000.
  8. Elidemir O, Colasurdo GN, Rossmann SN, Fan LL: Isolation of Stachybotrys from the lung of a child with pulmonary hemosiderosis, Pediatrics 104:964–966, 1999.
  9. Etzel RA: Mycotoxins, J Am Med Assoc 287:425–427, 2002.
  10. Etzel RA, Montana E, Sorenson WG, et al: Acute pulmonary hemorrhage in infants associated with exposure to Stachybotrys atra and other fungi, Arch Pediatr Adolesc Med 152:757–762, 1998.
  11. Etzel RA: Reducing malnutrition: time to consider potential links between stunting and mycotoxin exposure? Pediatrics 134(1):4–6, 2014.
  12. Flappan SM, Portnoy J, Jones P, Barnes C: Infant pulmonary hemorrhage in a suburban home with water damage and mold (Stachybotrys atra), Environ Health Perspect 107:927–930, 1999.
  13. Greenough G, McGeehin M, Bernard SM, et al: The potential impacts of climate variability and change on health impacts of extreme weather events in the United States, Environ Health Perspect 109(Suppl 2):191–198, 2001.
  14. Habiba A: Acute idiopathic pulmonary haemorrhage in infancy: Case report and review of the literature, J Paediatr Child Health 41:532–533, 2005.
  15. Haefliger P, Mathieu-Nolf M, Lociciro S, et al: Mass lead intoxication from informal used lead-acid battery recycling in dakar, Senegal, Environ Health Perspect 117:15–1540, 2009.
  16. Hendricks K: Fumonisins and neural tube defects in south Texas, Epidemiology 10:198–200, 1999.
  17. Hendricks KA, Simpson JS, Larsen RD: Neural tube defects along the Texas-Mexico border, 1993-1995, Am J Epidemiol 149:1119–1127, 1999.
  18. Hesseltine CW, Mehlman MA, editors: Mycotoxins in human and animal health, Park Forest, IL, 1977, Pathtox Publishers, pp 277–284.
  19. International Agency for Research on Cancer: Mycotoxins and human health, IARC Sci Publ 158:87–104, 2012.
  20. Joffe AZ: Foodborne diseases: alimentary toxic aleukia. In Rechcigle M, editor: Handbook of foodborne disease of biological origin, Boca Raton, FL, 1983, CRC Press, pp 351–495.
  21. Knapp JF, Michael JG, Hegenbarth MA, et al: Case records of the Children’s Mercy Hospital, Case 02-1999: a 1-month-old infant with respiratory distress and shock, Pediatr Emerg Care 15:288–293, 1999.
  22. Lewis L, Onsongo M, Njapau H, et al: Aflatoxin contamination of commercial maize products during an outbreak of acute aflatoxicosis in eastern and central Kenya, Environ Health Perspect 113:1763–1767, 2005.
  23. Missmer SA, Suarez L, Felkner M, et al: Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border, Environ Health Perspect 114:237–241, 2006.
  24. Missmer S, Hendricks KA, Suarez L, et al: Fumonisins and neural tube defects: preliminary results from the Texas Department of Health, Epidemiology 11:183–184, 2000.
  25. Novotny WE, Dixit A: Pulmonary hemorrhage in an infant following 2 weeks of fungal exposure, Arch Pediatr Adolesc Med 154:271–275, 2000.
  26. Sheffield PE, Landrigan PJ: Global climate change and children’s health: threats and strategies for prevention, Environ Health Perspect 119(3):291–298, 2011.
  27. Smith KR, et al: Human health impacts, adaptation, and co-benefits. In: climate change 2014: impacts, adaptation, and vulnerability. Part A: global and sectoral aspects. In Contribution of working group II to the fifth assessment report of the intergovernmental panel on climate change, Cambridge, U.K., 2014, Cambridge University Press, pp 709–754.
  28. Storey E, Dangman KH, Schenck P, et al: Guidance for Clinicians on the Recognition and Management of Health Effects Related to Mold Exposure and Moisture Indoors. Center for Indoor Environments and Health, University of Connecticut Health Center, 2004.
  29. Weiss A, Chidekel AS: Acute pulmonary hemorrhage in a Delaware infant after exposure to Stachybotrys atra, Del Med J 74:363–368, 2002.
  30. World Health Organization: Preventing disease through healthy environments—towards an estimate of the environmental burden of disease, Geneva, Switzerland, 2006, World Health Organization.
  31. World Health Organization: WHO guidelines for indoor air quality: dampness and mold, Copenhagen, Denmark, 2009.
  32. American College of Radiology: 2016 ACR appropriateness criteria. Äîñòóïíî íà ñàéòå: http://www.acr.org/Quality-Safety/Appropriateness-Criteria
  33. American College of Radiology: 2016 Practice parameters and technical standards. Äîñòóïíî íà ñàéòå: http://www.acr.org/Quality-Safety/Standards-Guidelines
  34. Becker SM: Protecting public health after radiation emergencies, BMJ 342:d1968, 2011
  35. Bernal B, Altman NR: Evidence-based medicine: neuroimaging of seizures, Neuroimaging Clin N Am 13:211–224, 2003
  36. Berrington de Gonzalez A, Mahesh M, Kim KP, et al: Projected cancer risks from computed tomographic scans performed in the United States in 2007, Arch Intern Med 169:2071–2077, 2009
  37. Bhatia S, Sklar S: Second cancers in survivors of childhood cancer, Nat Rev Cancer 2:124–132, 2002
  38. Boland GW, Thrall JH, Gazelle GS, et al: Decision support for radiologist report recommendations, J Am Coll Radiol 8(12):819–823, 2011
  39. Brady SL, Shulkin BS: Ultralow dose computed tomography attenuation correction for pediatric PET CT using adaptive statistical iterative reconstruction, Med Phys 42(2):558–566, 2015
  40. Brady SL, Moore BM, Yee BS, Kaufman RA: Pediatric CT: implementation of ASIR for substantial radiation dose reduction while maintaining Pre-ASIR image noise, Radiology 270(1):223–231, 2014
  41. Brady SL, Mirro AE, Moore BM, Kaufman RA: Pediatric CT: how to appropriately calculate effective dose for CT using either Size-specific dose estimates or Dose-length product, AJR 204:953–958, 2015
  42. Brady SL, Mohaupt TH, Kaufman RA: A comprehensive risk assessment method for pediatric patients undergoing research examinations using ionizing radiation: how we answered the institutional review board, AJR 204:W510–W518, 2015
  43. Brenner DJ, Hall EJ: Computed tomography—an increasing source of radiation exposure, N Engl J Med 357:2277–2284, 2007
  44. Christodouleas JP, Forrest RD, Ainsley CG, et al: Short-term and long-term health risks of nuclear-power-plant accidents, N Engl J Med 364(24):2334–2340, 2011
  45. Claus EB, Calvocoressi L, Bondy ML, et al: Dental x-rays and risk of meningioma, Cancer 118:4530–4537, 2012
  46. Cuthbertson DJ, Davidson J: What to tell patients about radioiodine therapy, BMJ 333:271–272, 2006
  47. Doll R, Wakeford R: Risk of childhood cancer from fetal irradiation, Br J Radiol 70:130–139, 1997
  48. Fahimi J, Herring A, Harries A, et al: Computed tomography use among children presenting to emergency departments with abdominal pain, Pediatrics 130(5):e10369–e11075, 2012.
  49. Fazel R, Krumholz HM, Wang Y, et al: Exposure to low-dose ionizing radiation from medical imaging procedures, N Engl J Med 36:849–857, 2009
  50. Frush DP, Slovis TL: Radiation bioeffects, risks and radiation protection in medical imaging in children. In Coley BD, editor: Caffey’s pediatric diagnostic imaging, ed 12, Philadelphia, 2014, WB Saunders
  51. Hasegawa A, Tanigawa K, Ohtsuru A, et al: Health effects of radiation and other health problems in the aftermath of nuclear accidents, with an emphasis on fukushima, Lancet 386:479–486, 2015
  52. Hall EJ: Radiation biology for pediatric radiologists, Pediatr Radiol 39(Suppl 1):S57–S64, 2009
  53. Hammer GP, Scheidemann-Wesp U, Samkange-Zeeb F, et al: Occupational exposure to low doses of ionizing radiation and cataract development: a systematic literature review and perspectives on future studies, Radiat Environ Biophys 52(3):303–319, 2013
  54. Harbon RW, Dreuil S, Bernier MO, et al: Patient radiation doses in paediatric interventional cardiology procedures: a review, J Radiol Prot 36(4):R131–R144, 2016
  55. Hendee WR, Becker GJ, Borgstede JP, et al: Addressing overutilization in medical imaging, Radiology 257(1):240–245, 2010.
  56. Hendee WR, O’Connor MK: Radiation risks of medical imaging: separating fact from fantasy, Radiology 264(2):312–321, 2012
  57. Hudson MM, Ness KK, Gurney JG, et al: Clinical ascertainment of health outcomes among adults treated for childhood cancer, JAMA 309(22):2371–2381, 2013
  58. Imaizumi M, Usa T, Tominaga T, et al: Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in hiroshima and nagasaki atomic bomb survivors 55–58 years after radiation exposure, JAMA 295:1011–1022, 2006
  59. ICRP, Nosslin B, Henrichs K, et al: ICRP publication 53: radiation dose to patients from radiopharmaceuticals, Ann ICRP 18(1–4):1–377, 1987
  60. ICRP, Mattsson S, Nosslin B, et al: ICRP publication 80: radiation dose to patients from radiopharmaceuticals addendum to ICRP 53, Ann ICRP 28(3):1–126, 1998
  61. ICRP, Mattsson S, Johansson L, et al: ICRP publication 106: radiation dose to patients from radiopharmaceuticals addendum 3 to ICRP 53, Ann ICRP 38(1–2):1–193, 2008
  62. ICRP, Alexakhin RM, Cousins C, et al: ICRP publication 103: the 2007 recommendations of the international commission on radiological protection, Ann ICRP 37(2–4):1–332, 2007
  63. ICRP, Khong PL, Ringertz H, et al: ICRP publication 121: radiological protection in paediatric diagnostic and interventional radiology, Ann ICRP 42(2):1–63, 2013
  64. Kal HB, Struikmans H: Radiotherapy during pregnancy: fact and fiction, Lancet Oncol 6:328–333, 2005
  65. Kamiya K, Ozasa K, Akiba S, et al: Long-term effects of radiation exposure on health, Lancet 386:469–476, 2015
  66. Karachaliou F, Simatos G, Batika P, et al: Endocrine consequences of childhood malignancies, J BUON 14:27–32, 2009
  67. Kleinerman RA: Radiation-sensitive genetically susceptible pediatric sub- populations, Pediatr Radiol 39(Suppl 1):S27–S31, 2009
  68. Koenig TR, Wolff D, Mettler FA, et al: Skin injuries from fluoroscopically guided procedures: part i: characteristics of radiation injury, AJR Am J Roentgenol 177:3–11, 2001
  69. Larson DB, Johnson LW, Schnell BM, et al: National trends in CT use in the emergency department: 1995-2007, Radiology 258(1):164–173, 2011
  70. Lin EC: Radiation risk from medical imaging, Mayo Clin Proc 85(12):1142–1146, 2010
  71. Linet MS, Kim KP, Rajaraman P: Children’s exposure to diagnostic medical radiation and cancer risk: epidemiologic and dosimetric considerations, Pediatr Radiol 39(Suppl 1):S4–S26, 2009
  72. Mathews JD, Forsythe AV, Brady Z, et al: Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage of 11 million australians, BMJ 346:1–18, 2013
  73. The Medical Letter: Potassium iodide for thyroid protection in a nuclear-accident, Med Lett Drugs Ther 53:25–26, 2011
  74. Mettler FA Jr: Medical resources and requirements for responding to radiological terrorism, Health Phys 89:488–493, 2005
  75. Mettler FA, Voelz GL: Major radiation exposure—what to expect and how to respond, N Engl J Med 346:1554–1561, 2002
  76. Miglioretti DL, Johnson E, Williams A, et al: The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk, JAMA Pediatr 167(8):700–707, 2013
  77. Miksys N, Gordon CL, Thomas K, Connolly BL: Estimating effective dose to pediatric patients undergoing interventional radiology procedures using anthropomorphic phantoms and MOSFET dosimeters, AJR 194:1315–1322, 2010
  78. Mirro AE, Brady SL, Kaufman RA: Full Dose-reduction potential of statistical iterative reconstruction for head CT protocols in a predominantly pediatric population, AJNR Am J Neuroradiol 37:1199–1205, 2016
  79. NCRP Report 174: Preconception and prenatal radiation exposure: health effects and protective guidance, 2013
  80. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of childhood cancer, N Engl J Med 355:1572–1582, 2006
  81. Ohtsuru A, Tanigawa K, Kumagai A, et al: Nuclear disasters and health: lessons learned, challenges, and proposals, Lancet 386:489–496, 2015
  82. Pierce DA, Preston DL: Radiation-related cancer risks at low doses among atomic bomb survivors, Radiat Res 154:178–186, 2000
  83. Pearce MS, Salotti JA, Little MP, et al: Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study, Lancet 380(9840):499–505, 2012
  84. Pierce DA, Shimizu Y, Preston DL, et al: Studies of the mortality of atomic bomb survivors. Report 12, part 1. Cancer: 1950–1990, Radiat Res 146:1–27, 1996
  85. Preston DL, Cullings H, Suyama A, et al: Solid cancer incidence in atomic bomb survivors exposed in utero or as young children, J Natl Cancer Inst 100(6):428–436, 2008
  86. Preston DL, Ron E, Yonehara S, et al: Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure, J Natl Cancer Inst 94:1555–1563, 2002
  87. Puch-Kapst K, Juran R, Phys D, et al: Radiation exposure in 212 very low and extremely low birth weight infants, Pediatrics 124:1556–1564, 2009
  88. Robison LL: Treatment-associated subsequent neoplasms among long-term survivors of childhood cancer: the experience of the childhood cancer survivor study, Pediatr Radiol 39(Suppl 1):S32–S37, 2009
  89. Shimizu Y, Kodama K, Nishi N, et al: Radiation exposure and circulatory disease risk: hiroshima and nagasaki atomic bomb survivor data, 1950–2003, BMJ 340:b5349, 2010
  90. Shore RE, Neriishi K, Nakashima E: Epidemiological studies of cataract risk at low to moderate radiation doses: (not) seeing is believing, Radiat Res 174(6):889–894, 2010
  91. Smith-Bindman R, Lipson J, Marcus R, et al: Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer, Arch Intern Med 169:2078–2086, 2009
  92. Sodickson A: CT radiation risks coming into clearer focus, BMJ 346:f3102, 2013
  93. Sodickson A, et al: Recurrent CT, Cumulative radiation exposure, and associated Radiation-induced cancer risks from CT of adults, Radiology 251(1):175–1784, 2009
  94. Turai I, Veress K, G?nalp B, et al: Medical response to radiation incidents and radionuclear threats, BMJ 328:568–572, 2004
  95. United Nations Information Service: Risk following exposure to radiation differs for adults and children, says UNSCEAR report. UNIS/OUS/216, 2013. Äîñòóïíî íà ñàéòå: http://www.unscear.org/docs/temp/ous216eweb.pdf
  96. Williams PM, Fletcher S: Health Effects of Prenatal Radiation Exposure, Am Fam Physician 82(5):488–493, 2010 Sep 1
  97. Williams CH, Frush DP: Compendium of national guidelines for imaging of the pediatric patient, Pediatr Radiol 42(1):82–94, 2012
  98. Zablotska LB, Bazyka D, Lubin JH, et al: Radiation and the risk of chronic lymphocytic and other leukemias among chornobyl cleanup workers, Environ Health Perspect 121:59–65, 2013
  99. Arora M, Austin C: Teeth as a biomarker of past chemical exposure, Curr Opin Pediatr 25:261–267, 2013
  100. Barker DJ: Developmental origins of adult health and disease, J Epidemiol Community Health 58:114–115, 2004
  101. Benbrook CM: Trends in glyphosate herbicide use in the United States and globally, Environ Sci Eur 28:3, 2016
  102. Braun JM, Kalkbrenner AE, Calafat AM, et al: Impact of early-life bisphenol a exposure on behavior and executive function in children, Pediatrics 128:873–882, 2011
  103. Carpenter DO: Hydraulic fracturing for natural gas: impact on health and environment, Rev Environ Health 31(1):47–51, 2016
  104. Carson R: Silent spring, Boston, 1962, Houghton Mifflin
  105. Centers for Disease Control and Prevention: Acute illness associated with insecticides used to control bed bugs–seven states, 2003-2010, MMWR Morb Mortal Wkly Rep 60:1269–1274, 2011
  106. Centers for Disease Control and Prevention: Acute illness and injury from swimming pool disinfectants and other chemicals–United States, 2002-2008, MMWR Morb Mortal Wkly Rep 60:1343–1347, 2011
  107. Centers for Disease Control and Prevention; National Biomonitoring Program. https://www.cdc.gov/biomonitoring/. (Accessed 7 June 2016)
  108. Centers for Disease Control and Prevention: Exposure to nitrogen dioxide in an indoor ice arena–new hampshire, 2011, MMWR Morb Mortal Wkly Rep 61:139–142, 2012
  109. Centers for Disease Control and Prevention: Fatal exposure to methylene chloride among bathtub refinishers–United States, 2000-2011, MMWR Morb Mortal Wkly Rep 61:119–122, 2012
  110. Centers for Disease Control and Prevention: Occupational phosphine gas poisoning at veterinary hospitals from dogs that ingested zinc phosphates–Michigan, Iowa, and washington, 2006-2011, MMWR Morb Mortal Wkly Rep 61:286–288, 2012
  111. Centers for Disease Control and Prevention: Health hazards associated with laundry detergent pods–United States, May-June 2012, MMWR Morb Mortal Wkly Rep 61:827–828, 2012
  112. Centers for Disease Control and Prevention: Acute pesticide-related illness resulting from occupational exposure to acrolein–washington and california, 1993-2009, MMWR Morb Mortal Wkly Rep 62:313–316, 2013
  113. Centers for Disease Control and Prevention: Exposures to discarded sulfur mustard munitions–mid-atlantic and new England states 2004-2012, MMWR Morb Mortal Wkly Rep 62:315–316, 2013
  114. Cimino AM, Boyles AL, Thayer KA, Perry MJ: Effects of neonicotinoid pesticide exposure on human health: a systematic review, Environ Health Perspect 125:2016. doi:10.1289/EHP515
  115. Cohn BA, La Merrill M, Krigbaum NY, et al: DDT exposure in utero and breast cancer, J Clin Endocrinol Metab 100:2865–2872, 2015
  116. Engel SM, Miodovnik A, Canfield RL, et al: Prenatal phthalate exposure is associated with childhood behavior and executive functioning, Environ Health Perspect 118(4):565–571, 2010
  117. Engel SM, Wetmur J, Chen J, et al: Prenatal exposure to organophosphates, paraoxonase 1, and cognitive development in childhood, Environ Health Perspect 119(8):1182–1188, 2011
  118. Eskenazi B, Marks A, Bradman A, et al: Organophosphate pesticide exposure and neurodevelopment in young Mexican-American children, Environ Health Perspect 115(5):792–798, 2007
  119. Etzel RA, Balk SJ, editors: Handbook of environmental health for children, ed 3, Elk Grove Village, IL, 2011, American Academy of Pediatrics
  120. Frank AL, Joshi TK: The global spread of asbestos, Ann Glob Heal 80:257–262, 2014
  121. Gauderman WJ, Urman R, Avol E, et al: Association of improved air quality with lung development in children, N Engl J Med 372:905–913, 2015
  122. Gore AC, Chappell VA, Fenton SE, et al: EDC-2: the endocrine Society’s second scientific statement on Endocrine-disrupting chemicals, Endocr Rev 36:E1–E150, 2015
  123. Grandjean P, Landrigan PJ: Neurobehavioural effects of developmental toxicity, Lancet Neurol 13:330–338, 2014
  124. Guyton KZ, Loomis D, Grosse Y, et al: Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate, Lancet Oncol 16:490–491, 2015
  125. Hanna-Attisha M, LaChance J, Sadler RC, Champney Schnepp A: Elevated blood lead levels in children associated with the flint drinking water crisis: A spatial analysis of risk and public health response, Am J Public Health 106:283–290, 2016
  126. Heindel JJ, Balbus J, Birnbaum L, et al: Developmental origins of health and disease: integrating environmental influences, Endocrinology 156:3416–3421, 2015
  127. Herbstman JB, Sj?din A, Kurzon M, et al: Prenatal exposure to PBDEs and neurodevelopment, Environ Health Perspect 118:712–719, 2010
  128. Jacobson JL, Jacobson SW: Intellectual impairment in children exposed to polychlorinated biphenyls in utero, N Engl J Med 335:783–789, 1996
  129. Kovats S, Depledge M, Haines A, et al: The health implications of fracking, Lancet 383:757–758, 2014
  130. Landrigan PJ, Goldman LR: Children’s vulnerability to toxic chemicals: a challenge and opportunity for health and environmental policy, Health Aff (Millwood) 30:842–850, 2011
  131. Landrigan PJ, Etzel RA: Textbook of Children’s environmental health, London, 2013, Oxford University Press
  132. Mishra PK, Samarth RM, Pathak N, et al: Bhopal gas tragedy: review of clinical and experimental findings after 25 years, Int J Occup Med Environ Health 22:193–202, 2009
  133. National Cancer Institute: SEER Database. http://seer.cancer.gov. (Accessed 6 May 2017)
  134. Paulson JA, Bins HJ, Brumberg HL, et al: Policy statement–chemical-management policy: prioritizing children’s health, Pediatrics 127:983–990, 2011
  135. Rauh VA, Perera FP, Horton MK, et al: Brain anomalies in children exposed prenatally to a common organophosphate pesticide, Proc Natl Acad Sci 109:7871–7876, 2012
  136. Roberts JR, Karr CJ, Paulson JA, et al: Policy Statement–pesticide exposure in children, Pediatrics 130:e1757–e1763, 2012
  137. Roberts JR, Karr CJ, Paulson JA, et al: Technical Report–pesticide exposure in children, Pediatrics 130:e1765–e1788, 2012
  138. Saunders PJ, McCoy D, Goldstein R, et al: A review of the public health impacts of unconventional natural gas development, Environ Geochem Health 2016. doi:10.1007/s10653-016-9898-x
  139. Schmidt CW: TSCA 2.0: a new era in chemical risk management, Environ Health Perspect 124:A182–A186, 2016
  140. Swan SH: Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans, Environ Res 108:177–184, 2008
  141. Trasande L, Liu Y: Reducing the staggering costs of environmental disease in children, estimated at $76.6 billion in 2008, Health Aff (Millwood) 30:863–870, 2011
  142. UN Environment: Global Chemicals Outlook—Towards Sound Management of Chemicals, 2013 http://web.unep.org/chemicalsandwaste/sites/unep.org.chemicalsandwaste/files/publications/GCO_web.pdf. (Accessed 30 March 2017).
  143. US Department of Housing and Urban Development: Advancing healthy housing—a strategy for action, Washington DC, 2013, HUD. http://portal.hud.gov/hudportal/documents/huddoc?id=stratplan_final_11_13.pdf
  144. Wood TJ, Goulson D: The environmental risks of neonicotinoid pesticides: a review of the evidence post-2013, bioRxiv 2017. doi:10.1101/098897
  145. Woodruff TJ, Darrow LA, Parker JD: Air pollution and postneonatal infant mortality in the United States, 1999–2002, Environ Health Perspect 116:110–115, 2007
  146. World Health Organization: The Impact of Pesticides on Health. http://www.who.int/mental_health/prevention/suicide/en/PesticidesHealth2.pdf?ua=1. (Accessed 12 April 2017)
  147. World Health Organization: Ambient air pollution: A global assessment of exposure and burden of disease, 2016. http://apps.who.int/iris/bitstream/10665/250141/1/9789241511353-eng.pdf?ua=1. (Accessed 17 April 2017)
  148. World Health Organization: Inheriting a sustainable world? Atlas on children’s health and the environment, Geneva, 2017, World Health Organization. http://apps.who.int/iris/bitstream/10665/254677/1/9789241511773-eng.pdf?ua=1. (Accessed 7 March 2017)
  149. Daly JB, Mackenzie LJ, Freund M, et al: Interventions by health care professionals who provide routine child health care to reduce tobacco smoke exposure in children: a review and Meta-analysis, JAMA Pediatr 170(2):138–147, 2016. doi:10.1001/jamapediatrics.2015.3342. Review. PMID: 26719991
  150. Farber HJ, Groner JA, Walley S, Nelson K: Section on tobacco control. Protecting children from nicotine, and tobacco smoke. Technical report, Pediatrics 136(5):e1439–e1467, 2015. doi:10.1542/peds.2015-3110. PMID 26504135
  151. Farber HJ, Walley SC, Groner JA, Nelson KE: Section on tobacco control. Clinical practice policy to protect children from tobacco, Nicotine, and tobacco smoke, Section on tobacco control, Pediatrics 136(5):1008–1017, 2015. doi:10.1542/peds.2015-3108. PMID: 26504137
  152. Homa DM, Neff LJ, King BA, et al: Vital signs: disparities in nonsmokers’ exposure to secondhand smoke—United States, 1999-2012, MMWR Morb Mortal Mkly Rep 64:13–108, 2015
  153. Jenssen B, Wilson K: Tobacco control and treatment for the pediatric clinician: practice, Policy, and research updates, Acad Pediatr 17(3):233–242, 2017. Epub 2017 Jan 6, doi:10.1016/j.acap.2016.12.010. PMID: 28069410
  154. Merianos A, Jandarov R, Mahabee-Gittens M: Secondhand smoke exposure and pediatric healthcare visits and hospitalizations, Am J Prev Med 2017. doi:10.1016/j.amepre.2017.03.020. [Epub ahead of print]. PMID 28532658
  155. Rosen LJ, Myers V, Winickoff JP, Kott J: Effectiveness of interventions to reduce tobacco smoke pollution in homes: a systematic review and Meta-analysis, Int J Environ Res Public Health 12(12):16043–16059, 2015. doi:10.3390/ijerph121215038. Review. PMID: 26694440
  156. Winickoff JP, Hipple B, Drehmer J, et al: The clinical effort against secondhand smoke exposure (CEASE) intervention: a decade of lessons learned, J Clin Outcomes Manag 19(9):414–419, 2012
  157. Winickoff JP, Nabi-Burza E, Chang Y, et al: Sustainability of a parental tobacco control intervention in pediatric practice, Pediatrics 134(5):933–941, 2014. Epub 2014 Oct 20, doi:10.1542/peds.2014-0639. PMID: 25332492
  158. U.S. Department of Health and Human Services: The health consequences of smoking—50 years of progress: a report of the Surgeon General, 2014. Available at: http://www.surgeongeneral.gov/library/reports/50-years-of-progress
  159. U.S. Department of Health and Human Services: Health consequences of involuntary exposure to tobacco smoke: a report of the surgeon general, Washington, DC, 2006, US Government Printing Office
  160. Adams P: In Bangladesh, funds dry up for arsenic mitigation research, Lancet 382:1693–1694, 2013
  161. Argos M, Kalra T, Rathouz PJ, et al: Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study, Lancet 376:252–258, 2010
  162. Bolger PM, Schwetz BA: Mercury and health, N Engl J Med 347:1735–1736, 2002
  163. Bose-O’Reilly S, McCarty KM, Steckling N, et al: Mercury exposure and children’s health, Curr Probl Pediatr Adolesc Health Care 40(8):185–216, 2010
  164. Bjorklund B, Aaseth J, Chirumbolo S, et al: Effects of arsenic toxicity beyond epigenetic modifications, Environ Geochem Health 40:955–965, 2017
  165. Carter M, Abdi A, Naz F, et al: A mercury toxicity case complicated by hyponatremia and abnormal endocrinological test results, Pediatrics 140(2):e20161402, 2017
  166. Centers for Disease Control and Prevention: Summary of the joint statement on thimerosal in vaccines. American Academy of Family Physicians, American Academy of Pediatricians, Advisory Committee on Immunization Practices, Public Health Service, MMWR Morb Mortal Wkly Rep 49:622–631, 2000
  167. Centers for Disease Control and Prevention: Mercury exposure among household users and nonusers of skin-lightening creams produced in Mexico–California and Virginia, 2010, MMWR Morb Mortal Wkly Rep 61:33–36, 2012
  168. Chen Y, Graziano JH, Parvez F, et al: Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study, BMJ 342:d2431, 2011
  169. Clarkson TW, Magos L, Myers GJ: The toxicology of mercury—current exposures and clinical manifestations, N Engl J Med 349:1731–1736, 2003
  170. Davidson PW, Myers GJ, Weiss B: Mercury exposure and child development outcomes, Pediatrics 113:1023, 2004
  171. Flanagan SV, Johnston RB, Zheng Y: Arsenic in tube well water in Bangladesh: health and economic impacts and implications for arsenic mitigation, Bull World Health Organ 90:839–846, 2012
  172. Fraser B: Cancer cluster in Chili linked to arsenic contamination, Lancet 379:603, 2012
  173. Gilbert-Diamond D, Cottingham KL, Gruber JF, et al: Rice consumption contributes to arsenic exposure in US women, Proc Natl Acad Sci USA 108:20656–20659, 2011
  174. Friedrich MJ: High mercury levels found in women around the world, JAMA 318(19):1857, 2017
  175. Golka K, Hengstler JG, Marchan R, et al: Severe arsenic poisoning: one of the largest man-made catastrophes, Arch Toxicol 84:583–584, 2010
  176. Heron J, Golding J: ALSPAC study team: thimerosal exposure in infants and developmental disorders: A prospective cohort study in the United Kingdom does not support a causal association, Pediatrics 114:577–583, 2004
  177. Huyck KL, Kile ML, Mahiuddin G, et al: Maternal arsenic exposure associated with low birth weight in Bangladesh, J Occup Environ Med 49:1097–1104, 2007
  178. Innis SM, Palaty J, Vaghri Z, et al: Increased levels of mercury associated with high fish intakes among children from Vancouver, Canada, J Pediatr 148:759–763, 2006
  179. Jackson BP, Taylor VF, Karagas MR, et al: Arsenic, organic foods, and brown rice syrup, Environ Health Perspect 120(5):623–626, 2012
  180. Karagas MR: Arsenic-related mortality in Bangladesh, Lancet 376:213–214, 2010
  181. Koirala S, Leinenkugel K: Acute mercury poisoning after home gold and silver smelting—Iowa, 2014, MMWR MORB MORTAL WKLY REP 64(40):1365–1366, 2015
  182. Kondo K: Congenital minamata disease: warnings from Japan’s experience, J Child Neurol 15:458–464, 2000
  183. Lai PY, Cottingham KL, Steinmaus C, et al: Arsenic and rice: translating research to address health care providers’ needs, J Pediatr 167(4):797–803, 2015
  184. Loewenberg S: In Bangladesh, arsenic poisoning is a neglected issue, Lancet 388:2336–2337, 2016
  185. Majumdar KK, Guha Mazumder DN: Effect of drinking arsenic-contaminated water in children, Indian J Public Health 56(3):223–226, 2012
  186. Myers GJ, Davidson PW, Strain JJ: Nutrient and methyl mercury exposure from consuming fish, J Nutr 137:2805–2808, 2007
  187. Parker SK, Schwartz B, Todd J, et al: Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data, Pediatrics 114:793–804, 2004
  188. Pichichero ME, Cernichiari E, Lopreiato J, et al: Mercury concentrations and metabolism in infants receiving vaccines containing thimerosal: a descriptive study, Lancet 360:1737–1740, 2002
  189. Rogan WJ, Brady MT: Drinking water from private wells and risks to children, Pediatrics 123:e1123, 2009
  190. Schober SE, Sinks TH, Jones RL, et al: Blood mercury levels in US children and women of childbearing age, 1999–2000, JAMA 289:1667–1674, 2003
  191. Stephen W, Munday S, Ford M, et al: Arsenic (heavy metals), chapter 88. In Nelson LS, Lewin NA, Howland MA, editors: Goldfrank’s toxicologic emergencies, ed 9, New York, 2011, McGraw-Hill
  192. Sue YJ, et al: Mercury (heavy metals), chapter 96. In Nelson LS, Lewin NA, Howland MA, editors: Goldfrank’s toxicologic emergencies, ed 9, New York, 2011, McGraw-Hill
  193. Tanaka H, Tsukuma H, Oshima A: Long-term prospective study of 6104 survivors of arsenic poisoning during infancy due to contaminated milk product in 1955, J Epidemiol 20:439–445, 2010
  194. Tewwll M, Spoto S, Wiese M, et al: Mercury poisoning at a home day care center—Hillsborough county, Florida, 2015, MMWR MORB MORTAL WKLY REP 66(17):433–435, 2017
  195. World Health Organization: Mercury and health: fact sheet #361, updated 2013.
  196. World Health Organization: Arsenic: fact sheet #372, 2012.
  197. ÀAP: Prevention of childhood lead toxicity Council on Environmental Health, Pediatrics 138(1):e20161493, 2016
  198. Berkowitz S, Tarrago R: Acute brain herniation from lead toxicity, Pediatrics 118:2548–2551, 2006
  199. Binns HJ, Campbell C, Brown MJ: Interpreting and managing blood lead levels of less than 10 microg/dL in children and reducing childhood exposure to lead: recommendations of the Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention, Pediatrics 120(5):e1285–e1298, 2007
  200. Canfield RL, Henderson CR Jr, Cory-Slechta DA, et al: Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter, N Engl J Med 348:1517–1526, 2003
  201. Centers for Disease Control and Prevention: Childhood blood lead levels in children <5 years—United States, 2009-2014, MMWR Morb Mortal Wkly Rep 66(3):1–7, 2017
  202. Centers for Disease Control and Prevention: Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention Report of the Advisory Committee on Childhood Lead Poisoning Prevention CDC.gov 2012
  203. Centers for Disease Control and Prevention: Lead poisoning of a child associated with use of a Cambodian amulet—New York City, 2009, MMWR Morb Mortal Wkly Rep 60(3):69–71, 2011
  204. Centers for Disease Control and Prevention: Death of a child after ingestion of a metallic charm—Minnesota, 2006, MMWR Morb Mortal Wkly Rep 55:340–341, 2006
  205. Centers for Disease Control and Prevention: Deaths associated with hypocalcemia from chelation therapy—Texas, Pennsylvania and Oregon, 2003–2005, MMWR Morb Mortal Wkly Rep 55:204–206, 2006
  206. Centers for Disease Control and Prevention: Lead exposure from indoor firing ranges among students on shooting teams—Alaska, 2002–2004, MMWR Morb Mortal Wkly Rep 54:577–579, 2005
  207. Centers for Disease Control and Prevention: Lead poisoning associated with use of litargirio—Rhode Island, 2003, MMWR Morb Mortal Wkly Rep 54:227–229, 2005
  208. Centers for Disease Control and Prevention: Lead poisoning associated with Ayurvedic medications—five states, 2000–2003, MMWR Morb Mortal Wkly Rep 53:582–586, 2004
  209. Centers for Disease Control and Prevention: Childhood lead poisoning associated with lead dust contamination of family vehicles and child safety seats—Maine, 2008, MMWR Morb Mortal Wkly Rep 58:890–893, 2009
  210. Centers for Disease Control and Prevention: Children with elevated blood lead levels related to home renovation, repair, and painting activities—New York State, 2006–2007, MMWR Morb Mortal Wkly Rep 58:55–58, 2009
  211. Centers for Disease Control and Prevention: Childhood lead poisoning associated with Tamarind county and folk remedies, MMWR Morb Mortal Wkly Rep 51:684–686, 2002
  212. Centers for Disease Control and Prevention: Fatal pediatric lead poisoning—New Hampshire, 2000, MMWR Morb Mortal Wkly Rep 50:457–459, 2001
  213. Centers for Disease Control and Prevention: Recommendations for blood lead screening of medicaid-eligible children aged 1–5 years: an updated approach to targeting a group at high risk, MMWR Morb Mortal Wkly Rep 58:1–13, 2009
  214. Centers for Disease Control and Prevention: Notes from the field: outbreak of acute lead poisoning among children aged <5 years—Zamfara, Nigeria, MMWR Morb Mortal Wkly Rep 59:846, 2010
  215. Committee on Drugs, AAP: Treatment guidelines for lead exposure in children, Pediatrics 96:155–160, 1995
  216. Committee on Environmental Health, AAP: Screening for elevated blood lead levels, Pediatrics 101:1072–1078, 1998
  217. Dietrich KN, Ware JH, Salganik M, et al: Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry, Pediatrics 114:19–26, 2004
  218. Environmental Defense Fund: Lead in food: a hidden health threat. June 15, 2017. https://www.edf.org/sites/default/files/edf_lead_food_report_final.pdf
  219. Florin TA, Brent RL, Weitzman M: The need for vigilance: the persistence of lead poisoning in children, Pediatrics 115:1767–1768, 2005
  220. Garcia P, Haile J: Lead poisoning in an infant associated with a metal bracelet—Connecticut, 2016, MMWR Morb Mortal Wkly Rep 66(34):916, 2017
  221. Global Lead Network: Alliance to end childhood lead poisoning.www.globalleadnet.org
  222. Grandjean P: Even low-dose lead exposure is hazardous, Lancet 376:855–856, 2010
  223. Hanna-Attisha M, LaChance J, Sadler RC, Champney Schnepp A: Elevated blood lead levels in children associated with the Flint drinking water crisis: a spatial analysis of risk and public health response, Am J Public Health 106(2):283–290, 2016. 26691115
  224. Hu H, T?llez-Rojo MM, Bellinger D, et al: Fetal lead exposure at each stage of pregnancy as a predictor of infant mental development, Environ Health Perspect 114:1730–1735, 2006
  225. Jacobs DE, Nevin R: Validation of a 20-year forecast of US childhood lead poisoning: updated prospects for 2010, Environ Res 102:352–364, 2006
  226. Karri SK, Saper RB, Kales SN: Lead encephalopathy due to traditional medicines, Curr Drug Saf 3:54–59, 2008
  227. Keller B, Faciano A, Tsega A, et al: Epidemiologic characteristics of children with blood lead levels ?45 ?g/dl, J Pediatr 180:229–234, 2017
  228. Kemper AR, Cohn LM, Fant KE, et al: Follow-up testing among children with elevated screening blood lead levels, JAMA 293:2232–2237, 2005
  229. Kennedy C, Yard E, Dignam T, et al: Blood lead levels among children aged <6 years—Flint, Michigan, 2013-2016, MMWR Morb Mortal Wkly Rep 65(25):650–654, 2016
  230. Kordas K: The “lead diet”: can dietary approaches prevent or treat lead exposure?, J Pediatr 185:224–231, 2017
  231. Kuehn BM: CDC advises pregnancy lead screening that targets populations at risk, JAMA 305(4):347, 2011
  232. Laraque D, Trasande L: Lead poisoning: successes and 21st century challenges, Pediatr Rev 26:435–443, 2005
  233. Lin CG, Schaider LA, Brabander DJ, et al: Pediatric lead exposure from imported Indian spices and cultural powders, Pediatrics 125:e828–e835, 2010
  234. Lozoff B, Jimenez E, Wolf AW, et al: Higher infant blood lead levels with longer duration of breastfeeding, J Pediatr 155:663–667, 2009
  235. Moszynski P: Mass lead poisoning in Nigeria causes “unprecedented” emergency, BMJ 341:223, 2010
  236. Nevin R: Understanding international crime trends: the legacy of preschool lead exposure, Environ Res 104(3):315–336, 2007
  237. Newman N, Jones C, Page E, et al: Investigation of childhood lead poisoning from parental take-home exposure from an electronic scrap recycling facility—Ohio, 2012, MMWR Morb Mortal Wkly Rep 64(27):743–745, 2015
  238. Reuben A, Caspi A, Belsky DW, et al: Association of childhood blood levels with cognitive function and socioeconomic status at age 38 years with IQ change and socioeconomic mobility between childhood and adulthood, JAMA 317(12):1244–1251, 2017
  239. Ruff HA, Bijur PE, Markowitz M, et al: Declining blood lead levels and cognitive changes in moderately lead-poisoned children, JAMA 269(13):1641–1646, 1993
  240. Saper RB, Phillips RS, Sehgal A, et al: Lead, mercury, and arsenic in US- and Indian-manufactured ayurvedic medicines sold via the Internet, JAMA 300:915–922, 2008
  241. Schnaas L, Rothenberg SJ, Flores MF, et al: Reduced intellectual development in children with prenatal lead exposure, Environ Health Perspect 114:791–797, 2006
  242. Selevan SG, Rice DC, Hogan KA, et al: Blood lead concentration and delayed puberty in girls, N Engl J Med 348:1527–1536, 2003
  243. Solon O, Riddell TJ, Quimbo SA, et al: Associations between cognitive function, blood lead concentrations, and nutrition among children in central Philippines, J Pediatr 152:237–243, 2008
  244. Tellez-Rojo MM, Bellinger DC, Arroyo-Quiroz C, et al: Longitudinal associations between blood lead concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City, Pediatrics 118:323–330, 2006
  245. U.S. Department of Housing and Urban Development Office of Healthy Homes and Lead Hazard Control: American Healthy Homes Survey Lead and Arsenic Findings. 2011
  246. Weiss D, Tomasallo CD, Meiman JG, et al: Elevated blood lead levels associated with retained bullet fragements – United States, 2003-2012, MMWR Morb Mortal Wkly Rep 66(5):130–132, 2017
  247. Woolf AD, Goldman R, Bellinger DC: Update on the clinical management of childhood lead poisoning, Pediatr Clin North Am 54:271–294, 2007
  248. Woolf AD, Woolf NT: Childhood lead poisoning in 2 families associated with spices used in food preparation, Pediatrics 116:e314–e318, 2005
  249. Wright JP, Dietrich KN, Ris MD, et al: Association of prenatal and childhood blood lead concentrations with criminal arrests in early adulthood, PLoS Med 5:e101–e266, 2008
  250. Berger KJ, Guss DA: Mycotoxins revisited: part I, J Emerg Med 28:53–62, 2005.
  251. Berger KJ, Guss DA: Mycotoxins revisited: part II, J Emerg Med 28:175–183, 2005.
  252. Diaz JH: Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings, Crit Care Med 33:419–426, 2005.
  253. Diaz JH: Syndromic diagnosis and management of confirmed mushroom poisonings, Crit Care Med 33:427–436, 2005.
  254. Evans N, Hamilton A, Bello-Villalba MJ, et al: Irreversible renal damage from accidental mushroom poisoning, BMJ 345:e5262, 2012.
  255. Maeta K, Ochi T, Tokimoto K, et al: Rapid species identification of cooked poisonous mushrooms by using real-time PCR, Appl Environ Microbiol 74:3306–3309, 2008.
  256. Persson H: Mushrooms, Medicine (Baltimore) 40:135–138, 2012.
  257. Schenk-Jaeger KM, Rauber-Luthy C, Bodmer M, et al: Mushroom poisoning: a study on circumstances of exposure and patterns of toxicity, Eur J Intern Med 23:e85–e91, 2012.
  258. Vo KT, Montgomery ME, Mitchell ST, et al: Amanita phalloides mushroom poisonings—northern california, December 2016, MMWR Morb Mortal Wkly Rep 66(21):549–552, 2017.
  259. Ward J, Kapadia K, Brush E: Salhanick SD. Amatoxin poisoning: case reports and review of current therapies, J Emerg Med 44:116–121, 2013.
  260. Barceloux D: Potatoes, tomatoes, and solanine toxicity, Dis Mon 55:391–401, 2009.
  261. Korpan YI, Nazarenko EA, Skryshevskaya IV, et al: Potato glycoalkaloids: true safety or false sense of security?, Trends Biotechnol 22:147–151, 2004.
  262. CDC: Cluster of ciguatera fish poisoning—north carolina, 2007, MMWR Morb Mortal Wkly Rep 58:283–285, 2009.
  263. Cole JB, Heegaard WG, Deeds JR, et al: Tetrodotoxin poisoning outbreak from imported dried puffer fish—minneapolis, Minnesota, 2014, MMWR Morb Mortal Wkly Rep 63(51 & 52):1222–1225, 2015.
  264. Friedman MA, Fernandez M, Backer LC, et al: An updated review of ciguatera fish poisoning: clinical, epidemiological, environmental, and public health management, Mar Drugs 15:1–41, 2017.
  265. Mullins ME, Hoffman RS: Is mannitol the treatment of choice for patients with ciguatera fish poisoning?, Clin Toxicol 55:947–955, 2017.
  266. Hungerford J: Scrombroid poisoning: a review, Toxicon 56:231–243, 2010.
  267. Jantschitsch C, Kinaciyan T, Manafi M, et al: Severe scombroid fish poisoning: an underrecognized dermatologic emergency, J Am Acad Dermatol 65(1):246–247, 2011.
  268. Wu SF, Chen W: An outbreak of scombroid fish poisoning in a kindergarten, Acta Paediatr Taiwan 44:297–299, 2003.
  269. Etharidge S: Paralytic shellfish poisoning: seafood safety and human health perspective, Toxicon 56:106–122, 2010.
  270. Isbister GK, Kiernan MC: Neurotoxic marine poisoning, Lancet Neurol 4:219–228, 2005.
  271. Kite-Powell HL, Fleming LE, Backer LC, et al: Linking the oceans to public health: current efforts and future directions, Environ Health 7(Suppl 2):56–70, 2008.
  272. Watkins SM, Reich A, Fleming LE, et al: Neurotoxic shellfish poisoning, Mar Drugs 6:431–455, 2008.
  273. Bret MM: Food poisoning associated with biotoxins in fish and shellfish, Curr Opin Infect Dis 16:461–465, 2003.
  274. Figgatt M, Hyde J, Dziewulski D, et al: Harmful algal bloom-associated illnesses in humans and dogs identified through a pilot surveillance system—New York, 2015, MMWR Morb Mortal Wkly Rep 66(43):1182–1184, 2017.
  275. Furey A, O’Doherty S, O’Callaghen K, et al: Toxins in shellfish: toxicological and health considerations, Toxicon 56:173–190, 2010.
  276. Mines D, Stahmer S, Shepherd SM: Poisonings: food, fish, shellfish, Emerg Med Clin North Am 15:157–177, 1997.
  277. An L, Li Z, Yang Z, et al: Melamine induced cognitive impairment associated with oxidative damage in rat’s hippocampus, Pharmacol Biochem Behav 102:196–202, 2012.
  278. Coulombier D, Heppner C, Fabiansson S, et al: Melamine contamination of dairy products in China—public health impact on citizens of the European union, Euro Surveill 13:1–2, 2008.
  279. Ingelfinger JR: Melamine and the global implications of food contamination, N Engl J Med 359:2745–2748, 2008.
  280. Lam HS, Ng PC, Chu WC, et al: Renal screening in children after exposure to low dose melamine in Hong Kong: cross sectional study, BMJ 337:a2991, 2008.
  281. Melamine and food safety in China [editorial], Lancet 373:353, 2009.
  282. Melamine-tainted milk product (MTMP) renal stone outbreak in humans [editorial], Hong Kong Med J 14:424–426, 2008.
  283. Melamine and cyanuric acid: toxicity, preliminary risk assessment and guidance on levels in food: WHO preliminary guidance, Geneva, 2008, World Health Organization.
  284. Yang VL, Battle D: Acute renal failure from adulteration of milk with melamine, ScientificWorldJournal 8:974–975, 2008.
  285. Adalija AA, Toner E, Inglesby TV: Clinical management of potential bioterrorism-related conditions. N Engl J Med 372(10):954-962, 2015
  286. American Academy of Pediatrics, Disaster preparedness advisory council. Medical countermeasures for children in public health emergencies, disasters, or terrorism. Pediatrics 137;e20154273, 2016. doi:10.1542/peds.2015-4273
  287. Baker MD: Antidotes for nerve agent poisoning: should we differentiate children from adults? Curr Opin Pediatr 19:211–215, 2007
  288. Bradley JS, Peacock G, Krug SE, et al: Pediatric anthrax clinical management, Pediatrics 133:e1411-e1436, 2014. doi:10.1542/peds.2014-0563
  289. Burklow TR, Yu CE, Madsen JM: Industrial chemicals: weapons of opportunity, Pediatr Ann 32:230–234, 2003
  290. Centers for Bioterrorism Preparedness Program Pediatric Task Force: Children in disasters: hospital guidelines for pediatric preparedness, ed 3, 2008. Äîñòóïíî ïî ññûëêå: http://www.nyc.gov/html/doh/downloads/pdf/bhpp/bhpp-hospital-pediatric-guidelines.pdf
  291. Cibulsky SM, Kirk MA, et al. Patient Decontamination in a Mass Chemical Exposure Incident: National Planning Guidance for Communities. ÌÇ è ñîöèàëüíûõ ñëóæá ÑØÀ è Ìèíèñòåðñòâî âíóòðåííåé áåçîïàñíîñòè ÑØÀ, 2016 ã., äîñòóïíî íà ñàéòå https://www.phe.gov/Preparedness/responders/Pages/patientdecon.aspx
  292. Cieslak TJ, Henretig FM: Bioterrorism, Pediatr Ann 32:154–165, 2003
  293. Cieslak TJ, Henretig FM: Ring-a-ring-a-roses: bioterrorism and its peculiar relevance to pediatrics, Curr Opin Pediatr 15:107–111, 2003
  294. Cieslak TJ, Jarrett DG, Schobitz EP Chemical, biological, radiological, and nuclear casualties. In: Pediatric surgery and medicine for hostile environments, Fuenfer MM, Creamer KM, eds. Borden Institute, Fort Sam Houston TX, 2017
  295. Endom EE Bioterrorism and the pediatric patient. Clin Pediatr Emerg Med 2013;14:102-117
  296. Geller RJ, Barthold C, Salers JA, et al: Pediatric cyanide poisoning: causes, manifestations, management and unmet needs, Pediatrics 118:2146–2158, 2006
  297. Gutmann A: Safeguarding children—pediatric research on medical countermeasures, N Engl J Med 368(13):1171–1173, 2013
  298. Hall AH, Dart R, Bogdan G: Sodium thiosulfate or hydroxocobalamin for the empiric treatment of cyanide poisoning? Ann Emerg Med 49:806–813, 2007
  299. Hamele M, Poss WB, Sweney J Disaster preparedness, pediatric considerations in primary balst injury, chemical, and biological terrorism. World J Crit Care Med 2014;3:15-23
  300. Kales SN, Christiani DC: Acute chemical emergencies, N Engl J Med 350:800–808, 2004
  301. Lee EC: Clinical manifestations of sarin nerve gas exposure, JAMA 290:659–662, 2003.
  302. Markenson D, Redlener I: Pediatric terrorism preparedness national guidelines and recommendations: findings of an evidence-based consensus process, Biosecur Bioterror 2:301–319, 2004
  303. Markenson D, Reynolds S: American academy of pediatrics committee on pediatric emergency medicine, Task force on terrorism: the pediatrician and disaster preparedness, Pediatrics 117:340–362, 2006
  304. Middaugh N, Petersen B, McCollum AM, Smelser C: Adverse reaction after vaccinia virus vaccination—New Mexico, 2016. MMWR Morb Mortal Wkly Rep 65(47):1351-1352, 2016
  305. Rotenberg JS, Newmark J: Nerve agent attacks on children: diagnosis and management, Pediatrics 112:648–658, 2003
  306. Russell D, Blaine PG, Rice P: Clinical management of casualties exposed to lung damaging agents: a critical review, Emerg Med J 23:421–424, 2006
  307. The Medical Letter: BioThrax and anthrasil for anthrax. Med Lett Drugs Ther 58(1494), 62, 2016
  308. The Medical Letter: Raxibacumab for anthrax, Med Lett Drugs Ther 55:27–28, 2013
  309. US Department of Health and Human Services: Decontamination guidance for chemical incidents. Accessed 7 June 2017 at: https://www.medicalcountermeasures.gov/barda/cbrn/prism
  310. Zarocostas J: Syria chemical attacks: preparing for unconscionable. Lancet 389:1501, 2017.
  311. Bartholomew RE, Wessely S, Rubin GJ: Mass psychogenic illness and the social network: is it changing the pattern of outbreaks?, J R Soc Med 105(12):509–512, 2012.
  312. Broderick JE, Kaplan-Liss E, Bass E: Experimental induction of psychogenic illness in the context of a medical event and media exposure, Am J Disaster Med 6(3):163–172, 2011.
  313. Engel CC, Adkins JA, Cowan DN: Caring for medically unexplained physical symptoms after toxic environmental exposures: effects of contested causation, Environ Health Perspect 110(Suppl 4):641–647, 2002.
  314. Mink JW: Conversion disorder and mass psychogenic illness in child neurology, Ann N Y Acad Sci 1304:40–44, 2013.
  315. Page LA, et al: Frequency and predictors of mass psychogenic illness, Epidemiology 21(5):744–747, 2010.
  316. Roach ES: Mass hysteria and the media: folie a troupeau?, Pediatr Neurol 49(1):6–7, 2013.
  317. Bjork A, Holman RC, Callinan LS, et al: Dog bite injuries among American Indian and Alaska native children, J Pediatr 162:1270–1275, 2013
  318. Centers for Disease Control and Prevention: Compendium of measures to prevent disease associated with animals in public settings, 2011: National Association of State Public Health Veterinarians, Inc, MMWR Recomm Rep 60(RR–04):1–24, 2011
  319. Dixon CA, Mahabee-Gittens EM, Hart KW, et al: Dog bite prevention: an assessment of child knowledge, J Pediatr 160:337–341, 2012
  320. Ellis R, Ellis C: Dog and cat bites, Am Fam Physician 90(4):239–243, 2014
  321. Eppley BL, Schleich AR: Facial dog bite injuries in children: treatment and outcome assessment, J Craniofac Surg 24:384–386, 2013
  322. Esposito S, Picciolli I, Semino M, et al: Dog and cat bite-associated infections in children, Eur J Clin Microbiol Infect Dis 32(8):971–976, 2013
  323. National Association of State Public Health Veterinarians: Compendium of animal rabies prevention and control, MMWR Recomm Rep 60(RR–06):1–17, 2011
  324. Nygaard M, Dahlin LB: Dog bite injuries to the hand, J Plast Surg Hand Surg 45:96–101, 2011.
  325. Paschos N, Makris E, Gantsos A, Georgoulis A: Primary closure vs. non-closure of dog bite wounds: a randomized controlled trial, Injury 45:237–240, 2014
  326. World Health Organization: WHO tries to quantify annual toll of animal bites, 2013. URL:http://ohsonline.com/articles/2013/02/25/who-tries-to-quantify-annual-toll-of-animal-bites.aspx
  327. Wu PS, Beres A, Tashjian DB, et al: Primary repair of facial dog bite injuries in children, Pediatr Emerg Care 27:801–803, 2011.
  328. Adam JK, Varan AK, Pong AL, McDonald EC: Fatal rat-bite fever in a child—san diego county, California, MMWR 63(50):1210–2014, 2013.
  329. Elliott SP: Rat bite fever and Streptobacillus moniliformis, Clin Microbiol Rev 20:13–22, 2007.
  330. Gaastra W, Boot R, Ho HT, et al: Rat bite fever, Vet Microbiol 133:211–228, 2009.
  331. Van Nood E, Peters SH: Rat-bite fever, Neth J Med 63:319–321, 2005.
  332. Vetter NM, Feder HM Jr, Ratzan RM: Rat bite fever caused by a kiss, Am J Emer Med 34(6):1190.e3–1190.e4, 2015.
  333. Damon IK: Status of human monkeypox: clinical disease, epidemiology and research, Vaccine 29(S4):D54–D59, 2011.
  334. Essbauer S, Pfeffer M, Meyer H: Zoonotic poxviruses, Vet Med 140:229–236, 2010.
  335. Parker S, Handley L, Buller RM: Therapeutic and prophylactic drugs to treat orthopoxvirus infections, Future Virol 3:595–612, 2008.
  336. Reed KD, Melski JW, Graham MB, et al: The detection of monkeypox in humans in the western hemisphere, N Engl J Med 350:342–350, 2004.
  337. Reynolds MG, Damon IK: Outbreaks of human monkeypox after cessation of smallpox vaccination, Trends Microbiol 20:80–87, 2012.
  338. Boesen K, Green KA, Shirazi F, et al: Special considerations. In Hoffman RA, Howland MA, Nelson LS, editors: Goldfrank’s toxicologic emergenices, ed 10, New York, 2015, Mc-Graw Hill, pp 1552–1556.
  339. Brush E, et al: Marine envenomations. In Hoffman RA, Howland MA, Nelson LS, editors: Goldfrank’s toxicologic emergenices, ed 10, New York, 2015, Mc-Graw Hill, pp 1487–1499.
  340. Darracq M, Clark RF, et al: A34: antidotes in depth. Antivenom: spider. In Hoffman RA, Howland MA, Nelson LS, editors: Goldfrank’s toxicologic emergenices, ed 10, New York, 2015, Mc-Graw Hill, pp 1480–1483.
  341. Darracq M, Clark RF, et al: A35: antidotes in depth. Antivenom: scorpion. In Hoffman RA, Howland MA, Nelson LS, editors: Goldfrank’s toxicologic emergenices, ed 10, New York, 2015, Mc-Graw Hill, pp 1484–1486.
  342. Hahn I, et al: Arthropods. In Hoffman RA, Howland MA, Nelson LS, editors: Goldfrank’s toxicologic emergenices, ed 10, New York, 2015, Mc-Graw Hill, pp 1461–1479.
  343. Levine M: Pediatric envenomations: don’t get bitten by an unclear plan of care, Pediatr Emerg Med Pract 11(8):1–12, 2014.
  344. The Medical Letter: Insect repellents, Med Lett 58:83–84, 2016.
  345. Mowry JB, Spyker DA, Brooks DE, et al: 2014 annual report of the American association of poison control Centers’ national poison data system (NPDS): 32nd annual report, Clin Toxicol 53(10):962–1146, 2015.
  346. Ruha A, Pizon A, et al: Native (US) venomous snakes and lizards. In Hoffman RA, Howland MA, Nelson LS, editors: Goldfrank’s toxicologic emergenices, ed 10, New York, 2015, Mc-Graw Hill, pp 1537–1546.
  347. Ruha A, Pizon A, et al: A37 antidotes in depth amtivenom: snakes (native [US] venomous crotaline and elapid. In Hoffman RA, Howland MA, Nelson LS, editors: Goldfrank’s toxicologic emergenices, ed 10, New York, 2015, Mc-Graw Hill, pp 1601–1610.
  348. Schulte J, Domanski K, Smith EA, et al: Childhood victims of snakebites: 2000-2013, Pediatrics 138(5):e20160491, 2016.

Òðóäû îòå÷åñòâåííûõ àâòîðîâ ïðè ïîäãîòîâêå ñòàòåé ïî ïåäèàòðèè äëÿ ïîëüçîâàòåëåé ñàéòà - íå èñïîëüçîâàëèñü, òàê êàê èõ âû âñåãäà ìîæåòå íàéòè â áèáëèîòåêàõ.

- Âåðíóòüñÿ â ðàçäåë "Ïåäèàòðèÿ"

Ðåäàêòîð: Èñêàíäåð Ìèëåâñêè. Äàòà îáíîâëåíèÿ ïóáëèêàöèè: 18.8.2024

Ìåäóíèâåð Ìû â Telegram Ìû â YouTube Ìû â VK Ôîðóì êîíñóëüòàöèé âðà÷åé Êîíòàêòû, ðåêëàìà
Èíôîðìàöèÿ íà ñàéòå ïîäëåæèò êîíñóëüòàöèè ëå÷àùèì âðà÷îì è íå çàìåíÿåò î÷íîé êîíñóëüòàöèè ñ íèì.
Ñì. ïîäðîáíåå â ïîëüçîâàòåëüñêîì ñîãëàøåíèè.